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A Veronica, 
alla quale ho richiesto tanto, 
 
and for my friends: 
 
"Once, in my father's bookshop, I heard a regular customer say that few things leave a 
deeper mark on a reader than the first book that finds its way into his heart. Those first 
images, the echo of words we think we have left behind, accompany us throughout our lives 
and sculpt a palace in our memory to which, sooner or later - no matter how many books we 
read, how many worlds we discover, or how much we learn or forget - we will return. For me 
those enchanted pages will always be the ones..." written during these years by my friends 
Giada, Laura, Caitlin and Rosaria. 
 
(From "The shadow of the wind" by Carlos Ruiz Zafón) 
  
 
  
ABSTRACT 
Depression is at the top position for "years lived with disability" (Smith, 2014). Its aetiology 
is unknown, but the pathogenesis implicates changes in glutamatergic neuronal plasticity. 
Glutamatergic plasticity likely mediates the effects of antidepressants acting through 
monoamines. Histamine is a monoaminergic neuromodulator able to regulate glutamatergic 
plasticity and synaptic transmission.  
The Flinders sensitive line (FSL) rat has face and predictive validity as model of depression 
when using traditional behavioural tests. However, these tests are usually missing complex 
explorative strategies that the animal performs in novel situations and that may be a relevant 
feature for a model of depression. We aimed to profile the FSL rat in terms of explorative 
strategies and coping styles displayed in a novel environment. The multivariate concentric 
square field™ (MCSF) consists of zones with different degrees of aversion. In the MCSF 
test, FSL rats showed lower exploratory drive, less recurrence to the shelter, and more risk 
assessment compared to Sprague Dawley rats, but no difference in risk-taking behaviours. In 
the novel cage test (consisting in a new bare environment) and in the home cage change test 
(to measure social behaviours), the FSL rat displayed a reactive coping style, described by 
immobility and lower aggression compared to Sprague Dawley rats. This profile shows 
similarities with temperaments and coping styles related to depression. 
Depression is linked to alteration of glutamatergic plasticity and similar alterations have been 
found in the hippocampus of FSL rats. Histamine H3 receptor (H3R) antagonists have 
displayed antidepressant properties in preclinical studies. We assessed the antidepressant 
properties of the H3R antagonist, clobenpropit, and its effect on hippocampal glutamatergic 
transmission in FSL rats. In the forced swim test, both systemic and hippocampal injections 
of clobenpropit reduced the immobility time. Clobenpropit improved memory in the novel 
object recognition and passive avoidance tests, with no effect on anxiety-related tests. 
Clobenpropit applied on hippocampal slices enhanced long-term synaptic potentiation (LTP), 
and, accordingly, in vivo administration increased the hippocampal levels of the NMDA 
receptor subunit GluN2A. Clobenpropit's effects both in the forced swim test and on LTP 
were prevented by blocking the hippocampal H1 and H2 receptors. In summary, clobenpropit 
exhibits antidepressant properties and regulates hippocampal glutamatergic plasticity, likely 
by an increase of histamine release and subsequent activation of the H1 and H2 receptors. 
Histamine receptors trigger intracellular signalling involved in the regulation of glutamatergic 
synaptic receptors, a mechanism that can affect synaptic strength. We assessed the 
histaminergic modulation of glutamatergic synaptic strength by recording miniature 
excitatory postsynaptic currents (mEPSCs) from CA1 pyramidal neurons in hippocampal 
slices from Sprague Dawley rats. The H1R, but not the H2R, agonist reduced mEPSC 
frequency, with no change of amplitude, suggesting a reduction of vesicle release probability. 
However, the paired-pulse facilitation (a measure of presynaptic release probability) was not 
altered by either the H1R or the H2R agonist, possibly due to a differential modulation of 
evoked versus spontaneous vesicle release. However, a postsynaptic origin of mEPSC 
frequency reduction cannot be excluded.  
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CHAPTER 1 
 
DEPRESSION IN CLINICAL PSYCHIATRY AND IN NEUROSCIENCE: towards a 
dimensional approach 
Diagnostic criteria for psychiatric diseases are codified in the Diagnostic and Statistical 
Manual of Mental Disorders that has been recently revised into the fifth edition (APA, 2013). 
Because of the lack of knowledge about aetiology, psychiatric diseases are still defined 
according to a categorical approach, i.e., the diagnosis is based on the presence of a number 
of signs and symptoms. As a direct consequence of such approach, psychiatric symptoms are 
often common to more than one categorical diagnosis and the borders among the different 
disorders are unclear. A classical example is represented by the depressive symptoms (loss of 
interest, mood deflection, sleep alterations and concentration problems) that are features of 
major depressive disorder, but also common in other psychiatric conditions (bereavement, 
bipolar disorder, schizophrenia, personality disorders). An analogous overlap also involves 
the treatment of choice: antidepressants are useful to treat depression as well as many anxiety 
disorders, while antipsychotics treat both schizophrenia and bipolar disorder (Stahl, 2013). 
Ultimately, the categorization of symptoms does not correspond to the biological processes 
and mechanisms underlying the disease; rather, drugs seem to affect mechanisms implicated 
transversally in multiple diseases. The underpinnings of mental disorders are the targets of 
investigation of neuroscience research. However, can neuroscience look for the cause of a 
disease that has been identified by lumping symptoms together? Are individual disorders 
really different if they commonly present overlapping symptoms? For instance, major 
depressive disorder and anxiety disorders share several symptoms (ruminative thoughts, 
concentration deficits, irritability and sleep problems), but they also overlap in aspects related 
to genetics, environmental risk factors, biological alterations, and pharmacological response 
(Hyman, 2007; Hettema, 2008). Such evidences have induced to reconsider the use of a 
categorical diagnosis in neuroscience research, in favour of a dimensional approach. 
According to this approach, mental disorders are not separated in distinct categories; instead 
disease groups are disposed along a continuum. Examples are: the continuum of healthy 
mental state - subtle cognitive deficits - schizotypal personality disorder - schizophrenia, or 
pure depressive disorder - mixed depressive/anxiety states - anxiety disorders (Hyman, 2007). 
Such dimensional approach has inspired the Research Domain Criteria (RDoC) stated by the 
National Institute of Mental Health in 2008 (Cuthbert and Insel, 2013). The aim was "to 
develop, for research purposes, new ways of classifying mental disorders based on 
dimensions of observable behaviours and neurobiological measures" (NIMH, 2008). Brain 
functions can be conceptually isolated and studied separately, each of them carried out by a 
specific brain circuitry, such as fear and defence, reward and appetitive behaviours. The 
RDoC system promotes the study of these single domains, instead of studying domains 
clustered in a complex syndrome/pathology as it was proposed by the categorical approach 
(Cuthbert and Insel, 2013).  
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The dualism "categorical/dimensional approach" has marked animal research. Animal models 
are far from ideally representing all the features of human disease, but the definition of 
validity criteria helps to estimate in which aspects the model recapitulates the human 
pathology. Following are the most commonly used validity criteria (Nestler and Hyman, 
2010): 
- Face validity: the animal model displays behavioural, anatomical, biochemical or 
neuropathological features of the human disease; 
- Predictive validity: the response of the animal model to treatments predicts the effect of 
those treatments in humans; 
- Construct validity: the model has been constructed by controlling or manipulating factors 
that are relevant (or thought to be relevant) for the aetiopathogenesis of the human 
pathology. 
Less commonly estimated are (Stewart and Kalueff, 2015): 
- Evolutionary validity: the model targets aspects of the disorder that are preserved across 
species; 
- Inter-relational validity: the features displayed by the model and resembling the human 
symptoms are part of inter-related domains, i.e., these domains are often altered together 
within the modelled disorder and may share pathophysiological overlaps;  
- Population validity: the model displays features that follow variability similar to humans. It 
derives from the genetic and environmental heterogeneity. 
Evidently, the validity criteria are inspired by the categorical approach that base psychiatric 
diagnoses: the more are the similarities with the human disease, the stronger is the validity of 
the model. However, modelling psychiatric diseases in animals has encountered the 
immediate problem that most of the symptoms in humans pertain to emotional and cognitive 
processes (e.g., negative thoughts, lack of interest and energy, difficulty of concentration, 
memory deficits). These symptoms are not unequivocally reproduced in animals: the 
experimenter's observation can only derive interpretations from animal behaviour (Nestler 
and Hyman, 2010). A dimensional approach that focuses on single domains across different 
pathologies may relatively bypass the "categorical problem", but still cognitive and emotional 
domains remain hardly accessible in animals. From here comes the need of finding new 
domains that may help in profiling animal models (Stewart and Kalueff, 2015). The construct 
of behavioural testing develops from the pre-constituted viewpoint of evoking an either-or 
response, in order to help the interpretation of the animal behaviour. These paradigms compel 
the animal responses into a restricted range of behaviours, and cut off a wide part of 
behaviours that may still be of importance for both understanding the patterns of responses 
and modelling the human pathology.    
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FITTING THE CONCEPTS OF DEPRESSION INTO ANIMAL MODELS 
Major depressive disorder is characterized by emotional symptoms (e.g., depressed or 
irritable mood, diminished interest or pleasure (anhedonia), feelings of guilt and 
worthlessness, and suicidal ideas), cognitive symptoms (lack of concentration, negative 
ruminative thoughts), homeostatic or neurovegetative symptoms (sleep abnormalities, loss of 
energy, appetite and weight), and psychomotor agitation or retardation. Among those, only 
anhedonia, homeostatic features and psychomotor behaviour can be assessed in rodent 
models, and represent the elements characterizing the model face validity (Nestler and 
Hyman, 2010). Some tests (forced swim test, tail suspension test and learned helplessness 
test) measure the avoiding/passive behavioural response of rodents to brief stressful situations 
(Duman, 2010). These responses are ascribed in the negative valence domains of the RDoC 
system and have predictive validity for screening antidepressants, which reduce the animal's 
negative response. When modelling depression in animals, an aspect to consider is the 
comorbidity of depression with anxiety disorders. Anxiety-like behaviour is evaluated by 
tests where the rodent can choose between aversive and secure zones: the avoidance of the 
aversive in favour of the secure compartment is considered as anxiety-like behaviour (Nestler 
and Hyman, 2010). Behavioural tests for animal models have been conceived to elicit animal 
behaviours that may represent an analogue of human symptoms. However, this approach 
leaves broad space to approximate anthropomorphic interpretation since depression in 
humans is associated to complex psychic experiences that are completely different and 
inaccessible in animals. Examples are represented by the sucrose preference test and the 
elevated zero-maze test. In the sucrose preference test, the lack of preference for sweet water 
over normal water is indicative of anhedonia, one of the features of depression. Although the 
paradigm construct seems to accurately target the anhedonic domain, the test has important 
limitations due to reproducibility and accuracy (Strekalova et al., 2011). It may be argued that 
anhedonia is represented by an increase in the threshold for pleasure; therefore anhedonic 
animals may paradoxically consume more sucrose in order to get satisfaction. In the elevated 
zero-maze test the preference to stay in the closed versus the open areas of the setup is 
interpreted as anxiety-like behaviour. Some studies have suggested that behaviours related to 
the assessment of the risk (stretched attend postures) can be affected by anxiolytics at doses 
lower than the doses required to change the recurrence to the open areas (Bickerdike et al., 
1994; Shepherd et al., 1994), thus bringing up the problem of specificity and sensitivity of the 
behavioural measurements. The tests are traditionally designed to derive variables concerning 
an either-or response (e.g., immobility versus mobility in the forced swim test, sucrose versus 
water in the sucrose consumption test, closed versus open areas in the traditional anxiety-
related tests). An alternative behavioural approach derives from ethology: it is based on the 
evaluation of a broad repertoire of explorative strategies that include exploratory behaviours, 
the use of shelter areas, risk-assessment and risk-taking behaviours, while coping with a 
novel situation (Steimer et al., 1997a; Meyerson et al., 2006; Marques et al., 2008). This 
approach aims to minimise interpretation and to give the free choice of exploration among 
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several options. Are behaviours captured by this approach relevant to better understand 
animal models? Are they relevant for modelling depression in animals?   
 
EXPLORATIVE STRATEGIES AND COPING STYLES IN DEPRESSION 
The exploration of a novel environment derives from the balance between risk/benefit 
evaluation and novelty-seeking drive (Hughes, 1997). When exposed to a novel situation, the 
animal response is described by certain variability within two extreme patterns. These 
patterns can be identified with trait characteristics, i.e., patterns of response that are stable 
over time and across different situations (Koolhaas et al., 2007). The individual variability 
could be described by the tier model: two independent dimensions identified with coping 
styles and emotional reactivity (Steimer et al., 1997b; Koolhaas et al., 2007). The coping style 
concepts derived from the individuation of two different patterns of response to stressful 
situations: the proactive response of fight/flight, characterized by aggression, territorial 
control, exploration of the environment, and active resolution of the conflicts; the reactive 
response of conservational/withdrawal, characterized by low aggression, immobility, and 
avoiding/passive resolution of conflicts. Coping styles have also been related to 
neuroendocrine responses to stress: proactive coping is associated with high adrenergic and 
low corticosteroid hormones, while reactive coping is associated with the opposite trends 
(Koolhaas, 2008). However, when analysed with a principal component analysis, the 
neuroendocrine responses to novelty exploration loaded with emotionality-related factors and 
not with coping styles (Van Reenen et al., 2005), suggesting that coping styles and emotional 
reactivity constitute two different dimensions. These concepts can be translated to humans. 
In the Cloninger's model for human temperaments and characters, the temperaments are 
largely determined by genetic factors, while the characters are built mainly on learning from 
life experiences and regard the development of self. Coping styles and the elements 
characterizing the response to novel situations can be identified in the temperaments of novel-
seeking and harm avoidance (Cloninger et al., 1993; Celikel et al., 2009). Notably, 
temperament and character constitute the individual personality, which has been related in 
different ways to psychiatric disorders. Depressed patients have reduced exploratory drive for 
novelty, and novelty seeking inversely correlates with the severity of depressive symptoms 
(Hansenne et al., 1999). Likewise, reactive coping style and harm avoidance are associated 
with increased risk for depression or higher scores of depressive symptoms (Celikel et al., 
2009; Nagase et al., 2009; Cairns et al., 2014; Roohafza et al., 2014). Despite the evidence 
that temperamental traits are linked to mood disorders, the nature of this association is largely 
speculative: temperamental traits may either predispose to the development of the disorder, 
represent early markers, or relate to the clinical manifestation of the disorder. The study of 
coping responses in animals identifies separate subgroups of individuals with distinct 
temperamental traits, which may be relevant for the development of models of depression 
(Koolhaas, 2008). These traits (such as exploratory activity and coping styles) are associated 
with certain behavioural and biological patterns, and are maintained over time. For instance, 
  5 
low exploratory mice (identified on the base of their object-directed exploratory activity in a 
novel environment) are characterized by more anxiety-like behaviours, lower locomotion, 
and worse performance at the passive avoidance. Moreover, they were less aggressive or 
submissive (Kazlauckas et al., 2005). These features can be ascribed in the reactive coping 
style with high emotionality (Koolhaas, 2008). The selective breeding of animals with 
extreme temperament traits has confirmed that the trait persists across generations and is 
associated to specific behavioural patterns (Steimer et al., 1997a; Veenema et al., 2003). 
Indeed, selective breeding for aggression distinguished two lines with different coping 
responses: long attack latency/low aggressive (LAL) mice displayed reactive responses and 
higher immobility in the forced swim test compared to short attack latency/high aggressive 
(SAL) mice (Veenema et al., 2003). The Roman lines selected for low avoidance profile have 
reduced novelty seeking and high emotional reactivity (Steimer et al., 1997a), while they 
were surprisingly more aggressive in the resident-intruder test (Coppens et al., 2013). This 
reinforces the hypothesis that emotional reactivity and coping styles are separate, but 
interacting, dimensions. Notably, coping styles and exploratory activity may predict the 
sensitivity to stress and drug response (Taghzouti et al., 1999; Veenema et al., 2003; 
Veenema et al., 2005). In summary, coping style and exploratory profile are crucial factors to 
understand the individual variability in animal testing and to interpret the behaviour 
expressed in different paradigms. Above all, they resemble depression-related temperamental 
traits, hence may help the translation between animal behavioural models and human 
depression.  
With this perspective, we looked at the exploratory behaviours and coping styles in an animal 
model of depression, the Flinders sensitive line (FSL) rat. The breeding selection of the FSL 
line targeted the sensitivity to cholinergic agents, with no intentional selectivity for 
behavioural profiles. However, the FSL rat was found to exhibit features modelling human 
depression (Overstreet and Wegener, 2013). We found that the FSL rat exhibits altered 
explorative strategies and reactive coping style that reinforce the FSL behavioural profiling as 
an animal model of depression.  
 
THE FLINDERS SENSITIVE LINE RATS 
The FSL was originally generated from Sprague Dawley (SD) rats by selective breeding on 
the basis of their sensitivity to the anticholinesterase diisopropyl fluorophosphate (Overstreet 
et al., 1979). The intention was to create a line that was resistant to the agent. Instead, the 
breeding generated a line that was more sensitive (the FSL) and a line (Flinders resistant line, 
FRL) with a response of the same extent than the control SD rats. It was then observed that 
FSL sensitivity was accounted for by an increase of cholinergic muscarinic receptors, with 
normal levels of acetilcholinesterase (Overstreet et al., 1984). Given the similarities of 
cholinergic abnormalities with depressed patients, FSL rats were further investigated as an 
animal model of depression. FSL rats display increased REM sleep, passive response to the 
forced swim test that is reverted by antidepressant treatments, and reduced weight and 
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appetite (Overstreet et al., 2005; Overstreet and Wegener, 2013). Cognitive symptoms of 
depression include impairment of concentration and of declarative and spatial memories 
(Austin et al., 2001; Bremner et al., 2004; Gould et al., 2007), which are common residual 
symptoms in depressed patients (McClintock et al., 2011). These symptoms have been related 
to hippocampal dysfunctions (Bremner et al., 2004; Deckersbach et al., 2006). Recent studies 
have found emotional and recognition memory impairments in the FSL rats (Eriksson et al., 
2012; Gomez-Galan et al., 2013). One of the core symptoms of depression, anhedonia, is not 
observed in FSL rats when tested for sweet intake and sucrose preference. However, after 
exposure to the chronic mild stress (a validated paradigm to induce depressive-like 
behaviours in animals), FSL rats exhibit anhedonia at a larger extent than control rats 
(Pucilowski et al., 1993). Therefore, the FSL rat shows face and construct validity in 
modelling many aspects of human depression and displays a good predictive validity for 
antidepressant response (Overstreet and Wegener, 2013). Anxiety dimension is often 
associated with depression and has been repeatedly assessed in FSL rats, with no univocal 
conclusion. In our study (see paper II) FSL rats exhibited increased anxiety-like behaviours in 
a number of traditional paradigms (Femenia et al., 2015). Instead, other groups have reported 
that FSL rats display less (Abildgaard et al., 2011) or no (Schiller et al., 1991) anxiety-related 
behaviours. This discordance leads to the possibility that different tests evoke different 
explorative strategies that influence the final behavioural outcome. Biochemical alterations in 
the serotonergic, cholinergic, and glutamatergic systems of FSL rats resemble analogous 
alterations found in depressed patients, and confer further validity to the animal model 
(Overstreet et al., 2005). The alterations of glutamatergic transmission in FSL rats will be 
described in chapter 2 in the context of the neuroplasticity hypothesis of depression. 
 
ALTERED EXPLORATIVE STRATEGIES AND REACTIVE COPING STYLE IN 
THE FSL RATS - (PAPER I) 
Summary 
Translational neuroscience is in need of alternative behavioural tests to validate animal 
models. Many aspects of human depression and anxiety symptoms are modelled in animals 
by interpreting the animal response in tests evoking an either-or response. An alternative 
approach derives from ethology: explorative strategies and coping styles are observed in an 
environment that allows the free expression of the animal's behavioural repertoire. We 
evaluated these aspects in the FSL rat, an animal model of depression, in comparison to SD 
rats, i.e., the rat strain that the FSL was derived from. For many years, FSL rats have been 
compared with the inbred resistant line, the FRL rat (Overstreet and Wegener, 2013). 
However, for our purpose, the use of the SD rats as control strain was more appropriate than 
the FRL rat. The choice of an outbred strain preserves individual variability in behavioural 
response to stress and in resilience/vulnerability to stressors within a group of animals. 
Moreover, FSL and FRL selective breeding was based on the responsiveness to cholinergic 
agents and may have consequently forced the segregation of genetic features related to 
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exploratory behaviours and coping styles. Since the relationship between behaviour and the 
cholinergic alterations is out of our scope, an outbred strain was preferred.  
The behavioural methodology consisted of three different tests: multivariate concentric 
square field™ (MCSF), novel cage, and home cage change tests.  
The MCSF test is constituted by an arena that includes shelter areas, elevated illuminated 
passages, enriched zones, open areas, and different light conditions. This multivariate context 
is able to evoke diverse strategies that include exploratory behaviours, risk assessment, risk 
taking, and shelter seeking (Figure 1). The test has been behaviourally validated with regard 
to the identification of risky and safe areas (Meyerson et al., 2006).  
 
(From Magara et al., 2015) 
Figure 1: picture of the MCSF arena with the defined zones. 1. center of the 
arena; 2-10. central circle and bridge (aversive zones); 3-5. corridors; 6. dark 
corner room (sheltered zone); 7. hurdle with the elevated hole board (to stimulate 
exploration); 8-9. slope and bridge entrance (to allow risk assessment towards 
the bridge.  
 
The MCSF test was sensitive in identifying subgroups that differed for particular behaviours 
in other tests. For instance, subgroups identified by the risk-assessment levels in the MCSF 
test showed differences in voluntary alcohol intake, with high risk assessment associated with 
higher alcohol intake (Momeni et al., 2014). The MCSF has also been used for behavioural 
profiling of selectively bred animals, where it evidenced different explorative strategies 
between different lines. For instance, the Alko alcohol-preferring/non-alcohol-preferring 
(AA/ANA) rat lines differed for many explorative strategies, with the AA line expressing 
lower general activity, exploratory activity and shelter seeking, and higher risk assessment 
and risk taking (Roman et al., 2012).  
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The novel cage test is based on scoring exploratory behaviours in a non-aversive environment 
(Marques et al., 2008). Marques et al. (2008) measured the free exploratory behaviours in the 
novel cage test (a novel home-cage without cage-mates) and in the concentric squared field 
test (similar to our MCSF arena). The exploratory behaviours included exploring and 
avoiding/passive behaviours that can be considered indicative of emotional reactivity and 
coping styles (proactive versus reactive) (Steimer et al., 1997a; Koolhaas et al., 1999; 
Marques et al., 2008). They characterized mouse-strain differences in both the novel cage and 
the concentric square field tests, with a good correspondence between tests. Steimer et al. 
(1997) measured exploratory activity (as an indirect measure of proactive coping) and 
emotional reactivity in a "small open field". It consisted in an illuminated box in order to 
create a mild aversive environment. The test showed differences between rat lines selectively 
bred on the basis of their active avoidance response (Roman high/low avoidance lines) 
(Steimer et al., 1997a). In our study, the aim was to expose the animal to a novel environment 
with minimal incentives or aversive elements, so that exploratory behaviours were mainly 
driven by the internal motivational state (Hughes, 1997) and reflected the expression of 
coping styles. Therefore, for our novel cage test, the apparatus consisted in a symmetrical 
small open field similar to the one used by Steimer et al. (1997), but with dimmed lights, and 
tall, opaque walls to allow for rearing and to protect from external visual cues.  
The home cage change test aimed to score social behaviours elicited by the change of cage. A 
new home cage is free of all "familiar" odours that the rat uses to mark and establish 
dominance (Burn et al., 2006). Therefore, the change of cage intensifies the expression of 
dominant-subordinate behaviours (Craig, 1986). The type of social behaviours displayed by 
the animals were scored and classified according to previously defined categories (Koolhaas 
et al., 1980; Fernandez-Espejo and Mir, 1990).  
In the MCSF test, the exploration of FSL rats was slightly altered compared to SD rats. FSL 
rats exhibited reduced exploratory drive and a strategy of exploration with more risk-
assessment behaviour and less recurrence to the shelter. When the rats were re-exposed to the 
MCSF test, the exploration strategies of FSL rats were similar to SD rats. Indeed, FSL rats 
increased the exploratory activity and the shelter seeking in the second compared to the first 
trial, thus reaching the SD rat's level. FSL rats used more stretched attend postures as risk 
assessment behaviour, but they explored the risk areas of the arena to the same extent of SD 
rats. Therefore, the behaviour exhibited by the FSL rat in the MCSF test indicates a slower 
explorative strategy, but it does not describe an avoiding, anxiety-related profile. FSL rats 
demonstrated behavioural flexibility by learning from the first exposure to the arena and 
consequently increasing their exploratory behaviour. In the novel cage test, FSL rats 
exhibited reduced exploratory activity (characterized by less investigative behaviour) and a 
reactive coping style compared to SD rats. The reactive coping style of FSL rats was also 
expressed by reduced aggressive behaviours, cage-mate avoidance, and burrowing in the 
home cage change test. Burrowing is considered a proactive defensive behaviour acted in 
anticipation of a potential threat (Dudek et al., 1983). Instead, stretched attend postures are 
risk-assessment strategies related to high emotionality and are used to search for and 
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acknowledge potential threats (Blanchard and Blanchard, 1989). Burrowing behaviour in the 
home cage change test and stretched attend postures in the MCSF test were inversely 
correlated. In conclusion, the FSL rat is characterized by low exploratory drive and a reactive 
coping style. During exposure to novelty, the reactive coping style is expressed by higher 
immobility, less proactive strategies (such as recurrence to a home base, investigative 
behaviour, anticipatory defensive burrowing), and high emotional reactivity during the 
evaluation of risk/benefit balance. In social contexts, reactive coping is expressed by 
avoidance and less aggressive behaviours. 
 
Implications 
The FSL rat's behavioural profile has previously evidenced low novelty-induced and goal-
directed exploration (Overstreet, 1986; Gomez-Galan et al., 2013). In agreement, we found 
that FSL rats display low exploratory drive and a reactive coping style during exploration of a 
novel environment and in social dominant-subordination behaviours. These features may be 
related with the FSL sensitivity to antidepressants. Indeed, in a previous study (Taghzouti et 
al., 1999), SD rats were grouped by exploratory levels exhibited in a novel environment. Low 
exploration was associated with a passive response (high immobility) in the forced swim test. 
The response in the forced swim test can be considered as an expression of coping style, and 
a drug-induced reduction of immobility time could be due to a switch in coping response 
(Koolhaas et al., 2007). Indeed, fluoxetine reduced the immobility of low-exploring rats in 
the forced swim test, while it increased the immobility of high-exploring rats (Taghzouti et 
al., 1999). The serotonin 5HT1A receptor agonist 8-OH-DPAT exerted a similar differential 
effect: it reduced the immobility time of LAL mice (that exhibit a reactive coping style in the 
active avoidance test and in the defensive burying test (Benus et al., 1991; Sluyter et al., 
1996)), but not of SAL mice (that exhibit a proactive coping style) (Veenema et al., 2005). In 
agreement, the FSL rat, which is characterized by a reactive coping style and low exploratory 
drive, has good predictive validity for the antidepressant action of drugs (Overstreet and 
Wegener, 2013). The reactive coping style of LAL mice is associated with reduced 
expression of the 5HT1A receptor in the hippocampus and prefrontal cortex compared to 
SAL mice (Korte et al., 1996), which may explain the different behavioural responses to 
serotonergic drugs (Veenema et al., 2005). Notably, both FSL rats and LAL mice differed 
from their respective control lines in the hypothermic response to 8-OH-DPAT, with the 
former more sensitive (Overstreet, 2002) and the latter less sensitive (van der Vegt et al., 
2001). As earlier described, a reactive coping style is associated to higher levels of 
corticosterone and lower levels of adrenaline in response to stress (Koolhaas et al., 1999), and 
to a different behavioural response to stress compared to animals with a proactive coping 
style (Veenema et al., 2003). It seems that coping style may be associated with a different 
resilience/vulnerability balance for the development of some stress-related diseases 
(Koolhaas et al., 1999; Veenema et al., 2003). Taken together, these results indicate that 
coping styles are associated with different levels of activation of neurotransmitter systems, 
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and both may explain animal responses to experimental testing, exposure to stress and drugs. 
These patterns of responses may be relevant both for the FSL rat and for other depression 
models.   
We have evidenced that the FSL rat performs risk-taking behaviour to the same extent as SD 
rats in the MCSF test, but with greater risk assessment. In the next chapter, we will discuss 
that FSL rats have displayed anxiety-like behaviours in the novelty suppressed feeding, social 
interaction, and light/dark box tests (paper II: Femenia et al., 2015). A possible explanation 
may derive from differences in the explorative strategies expressed in these tests. Exploratory 
responses to novelty are executed through sequences of behavioural strategies, such as choice 
of a home base for exploration, evaluation risk/benefits, and risk-assessment behaviours 
(Blanchard and Blanchard, 1988; Eilam and Golani, 1989; Drai et al., 2001). Laboratory 
behavioural tests may interfere with these sequences by curtaining the expression of animal 
behaviour repertoire to few responses. The significance of either-or responses may not be 
generalized to other contexts where the animal has a wider choice to freely express its 
exploratory behavioural strategies. This hypothesis is discussed in the paper I in the 
paragraph "Risk-assessment strategies and coping styles influence the interpretation of 
anxiety-related tests" (Magara et al., 2015).  
The FSL rat's explorative strategies and reactive coping style may represent targets for 
evaluating antidepressant drugs and may also help to interpret FSL behaviour expressed in 
traditional tests. Explorative strategies and coping styles may be considered as further 
domains for the validation of animal models of depression and of antidepressant drugs. 
Although not reported in the categorical definition of diagnostic criteria for human diseases, 
explorative strategies and coping styles represent evolutionary-preserved features. They may 
be potentially relevant for the resilience/vulnerability to stressors.  
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CHAPTER 2 
 
THE BIOCHEMISTRY OF DEPRESSION: monoamines and glutamatergic 
neuroplasticity 
For many years the pathogenesis of depression has been explained by the so-called 
"monoamine hypothesis", for which depression originates from depletion of the monoamines, 
i.e., serotonin and the catecholamines noradrenaline and dopamine (Baumeister et al., 2003; 
Racagni and Popoli, 2008). The monoamine hypothesis of depression was derived by two 
serendipitous discoveries in the 1950s: reserpine, used as antihypertensive drug, could cause 
depressive symptoms and depletes serotonin and catecholamine; iproniazid, used as 
antituberculosis drug, treated depressive symptoms (apathy, anorexia, feeling of well-being) 
and inhibits the monoamine oxidase, the enzyme that catabolises monoamines. Accordingly, 
the major drugs currently available for the treatment of depression are inhibitors of 
monoamine reuptake (for instance, selective serotonin reuptake inhibitors, SSRI; 
serotonin/noradrenaline reuptake inhibitors, SNRI). However, alteration in monoamine levels 
in depression has not yet been confirmed and the increase of monoamines is not sufficient to 
elicit an antidepressant effect. Indeed, while antidepressant drugs acutely increase 
monoamine levels, the antidepressant effect has a latency of several weeks. This evidence 
indicates that the actual therapeutic effect is underlain by neuroplasticity mechanisms, i.e., 
slow changes occurring within days in response to the perturbation created by the 
antidepressant drug. These changes may involve postsynaptic receptor adaptation, 
transcriptional and epigenetic modifications, neurotrophic factors and neurogenesis, 
morphological changes of neuronal spines and dendrites, and synaptic transmission (Racagni 
and Popoli, 2008). The neuroplasticity hypothesis accounts both for maladaptive plasticity (at 
the origin of the pathogenesis of depression) and for compensatory/beneficial plasticity 
(generated by antidepressants), which likely involve the glutamatergic transmission 
(Sanacora et al., 2012). The first suggestions of the involvement of the glutamatergic system 
in depression came from the observation that the NMDA receptor (NMDAR) is implicated in 
antidepressant responses. NMDAR antagonists were efficacious in animal tests predictive of 
an antidepressant activity (Trullas and Skolnick, 1990). Moreover, adaptation of the NMDAR 
complex consistently occurred after chronic, but not acute, administration of antidepressants 
(Paul et al., 1994). These discoveries were later strengthened by clinical evidences: in 
depressed patients, ketamine (NMDAR non-competitive antagonist) exerts a fast 
antidepressant effect that lasts long after the drug has been eliminated (Berman et al., 2000; 
Zarate et al., 2006). The brief pharmacological manipulation of glutamatergic transmission by 
ketamine triggers rapid mechanisms of synaptic plasticity (Autry et al., 2011; Nosyreva et al., 
2013) that may persist for long time underling the antidepressant effect (Li et al., 2010; 
Duman et al., 2012; Kavalali and Monteggia, 2015). The involvement of glutamatergic 
transmission in depression is further supported by the morphological neural alterations found 
in patients. In patients with depression, brain areas related to emotional/cognitive processing 
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and stress-responses (i.e., frontal areas and hippocampus) show volumetric reduction, glial 
loss and neuronal atrophy (Rajkowska, 2000; Rajkowska and Miguel-Hidalgo, 2007; 
Koolschijn et al., 2009). These alterations are likely to involve glutamate transmission, since 
the vast majority of synaptic connections in these areas are glutamatergic (Orrego and 
Villanueva, 1993; Douglas and Martin, 2007). Indeed, glial loss in depressed patients has 
been associated with reduction of the glial glutamate transporters (EAAT1 and EAAT2, also 
called GLAST and GLT-1, respectively) that provide for the reuptake of extrasynaptic 
glutamate (Rajkowska and Miguel-Hidalgo, 2007). Excessive levels of extrasynaptic 
glutamate trigger excitotoxicity mechanisms and neurodegeneration, likely underlying the 
development of the depressive disorder and ultimately leading to neuronal atrophy and a 
reduction of glutamatergic transmission (Sanacora et al., 2012). The causal relation among 
glial loss, reduced glutamate reuptake, increased glutamate transmission, and excitotoxicity is 
missing, but it is likely that some factors (genetic susceptibility or environmental stress) may 
produce adaptive plasticity mechanisms that, if challenged repeatedly, will result in 
maladaptive plasticity (Popoli et al., 2012). According to the neuroplasticity hypothesis, 
changes in glutamatergic neuronal plasticity may mediate the therapeutic effects of classical 
antidepressants that target the monoaminergic systems of serotonin and noradrenaline (Berton 
and Nestler, 2006). Histamine is a monoaminergic neuromodulator that has been far less 
studied in regard to depression, but has relevant effects on glutamatergic plasticity (Haas et 
al., 2008). 
 
HISTAMINE IN THE BRAIN 
Histaminergic neurons are localized in the tuberomammillary nucleus of the hypothalamus 
and project widely throughout the brain, including to the hippocampus (Purves et al., 2001). 
Histamine receptors are G-protein coupled receptors classified in 4 subtypes (Brown et al., 
2001). The H1 and H2 receptors (Gq- and Gs- coupled, respectively) are classically 
considered postsynaptic receptors. They are diffusely expressed in the brain, with some local 
differences: in comparison with the H2 receptors, the H1 receptor is more expressed in the 
cortex (layer IV) and the thalamus, but less expressed in the superficial layers of the cortex 
and in the striatum. The H4 receptor is coupled with a Gi-protein. It is mainly expressed in 
peripheral immunological tissues and cells, while its expression in the central nervous system 
is mainly limited to the dentate gyrus, thalamus and layer IV of the cortex (Connelly et al., 
2009). The H3 receptor is a presynaptic auto-receptor (localized on histamine-releasing 
varicosities) and hetero-receptor (localized on axons releasing other neurotransmitters, such 
as glutamate, acetylcholine, and GABA) (Haas et al., 2008). It is also localized 
postsynaptically on the somata and dendrites of histaminergic tuberomammillary neurons and 
possibly on other neurons (for instance, the striatal medium spiny neurons (Pillot et al., 
2002)). The H3 receptor is coupled with a Gi-protein that, when stimulated, inhibits N- and 
P-type calcium channels (Takeshita et al., 1998) and reduces the activity of the adenylate 
cyclase (Torrent et al., 2005). Through these mechanisms, the H3 receptors reduce 
  13 
neurotransmitter release from histaminergic and non-histaminergic terminals, and reduce cell 
firing and histamine synthesis in histaminergic neurons (Haas et al., 2008). The H3 receptor 
has constitutive activity, i.e., the Gi-protein coupled to the receptor is tonically active and 
partially inhibits the production of cAMP by adenylate cyclase in absence of the receptor 
agonist (Morisset et al., 2000; Moreno-Delgado et al., 2006). The H3 receptor can activate 
phosphokinase B (PKB, also called Akt, resulting in inhibition of the glycogen synthase 
kinase GSK3) (Bongers et al., 2007), phospholipase PLA2 (with the production of 
arachidonic acid) (Morisset et al., 2000), and the Ras/MEK/ERK cascade (Giovannini et al., 
2003). These pathways have a prominent role in plasticity mechanisms (Thomas and 
Huganir, 2004; Richter and Klann, 2009; Allyson et al., 2012), thus the H3 receptor may 
represent a target to modulate neuronal plasticity.  
Histamine neurotransmission regulates cognitive functions (motivation, arousal, learning and 
memory processes) and autonomic functions (sleep/wake cycle, food intake, 
thermoregulation) (Brown et al., 2001). Notably, many of these processes regulated by 
histamine are altered in depression, which is characterized by lack of motivational drive, 
difficulty of concentration, deficit in episodic memory, insomnia or hypersomnia, reduced 
body weight or increased food intake (APA, 2013). Acting on the histaminergic transmission 
may either directly impact the symptoms of depression or indirectly modulate glutamatergic 
plasticity mechanisms that are relevant for the antidepressant response. 
 
THE H3 RECEPTOR AS PHARMACOLOGICAL TARGET FOR DEPRESSION 
The H3 receptor is widely expressed throughout the brain. It inhibits the release of histamine 
as well as of many other neurotransmitters (dopamine, serotonin, acetylcholine, glutamate) 
(Esbenshade et al., 2008). Deficit of these neurotransmitters are linked to cognitive symptoms 
in many mental disorders. Due to its constitutive activity, the H3 receptor can be 
pharmacologically targeted to either antagonize the binding of endogenous histamine (by 
H3R neutral antagonists) or reduce the intrinsic activity of the receptor (by H3R inverse 
agonists) (Moreno-Delgado et al., 2006). The H3R antagonists/inverse agonists have been 
studied in the hypothesis that they could improve cognitive symptoms by disinhibition of 
neurotransmitter release. Tests in animal models have demonstrated that H3R antagonists 
improve performances related to several cognitive domains, i.e., recognition memory, 
working memory, and spatial orientation (Esbenshade et al., 2006). Given the promising 
results from experimental studies, the H3R antagonists have been tested in clinical trials to 
evaluate the cognitive effects in Alzheimer disease and schizophrenia (Tiligada et al., 2011) 
(www.clinicaltrials.gov). Moreover, some studies have tested the antidepressant effect of the 
H3R antagonists in animals. Clobenpropit and thioperamide (H3R antagonists/inverse 
agonists) reduced the immobility time of mice in the forced swim test (Lamberti et al., 1998; 
Pérez-García et al., 1999). New H3R antagonists have been reported to exert antidepressant-
like effects (Gao et al., 2013) and reduce anxiety-like behaviours in the open field, elevated 
plus maze and novelty suppressed feeding tests (Bahi et al., 2014). Many aspects of the 
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therapeutic mechanisms of the H3R antagonists are still not clear: would they ameliorate the 
behavioural phenotype and glutamatergic transmission/plasticity alterations of animal models 
of depression? Would their effect be mediated by modulating the release of histamine or 
other neurotransmitters?  
 
THE NEUROPLASTICITY HYPOTHESIS OF DEPRESSION IN REGARD TO THE 
FSL RATS    
The FSL rat model presents glutamatergic alterations of synaptic transmission and plasticity 
in the hippocampus (Gomez-Galan et al., 2013), resembling aspects that have been connected 
with depression pathogenesis. Reduced hippocampal volume has been associated with 
depression (Campbell et al., 2004; Stockmeier et al., 2004), and the hippocampus shows 
atrophic signs and alterations of glutamatergic transmission and plasticity in animal models 
of depression (Dranovsky and Hen, 2006; Qiao et al., 2014). FSL rats have increased 
frequency of hippocampal synaptic inputs onto CA1 pyramidal neurons and impaired long-
term synaptic plasticity (LTP) at CA3-CA1 connections. These alterations in FSL rats have 
been associated with astrocyte reactivity, with consequent reduction of D-serine release by 
astrocytes (necessary for LTP) and decreased expression of the glutamate transporter GLAST 
(responsible for the increase of the excitatory inputs) (Gomez-Galan et al., 2013). In 
agreement with the impaired hippocampal plasticity, FSL rats have shown deficits in 
recognition memory in the novel object recognition test and reduced emotional memory in 
the passive avoidance test (Eriksson et al., 2012; Gomez-Galan et al., 2013). Our study 
focused on the potential antidepressant properties of the histamine H3 receptor antagonist, 
clobenpropit, and its modulation on glutamatergic transmission and plasticity in the FSL rat 
model. 
 
HIPPOCAMPAL-DEPENDENT ANTIDEPRESSANT ACTION OF THE H3 
RECEPTOR ANTAGONIST CLOBENPROPIT IN A RAT MODEL OF 
DEPRESSION (PAPER II) 
Summary 
Depression may arise from the dysregulation of glutamatergic transmission and plasticity 
(Sanacora et al., 2012). The hippocampus presents important alterations both in depressed 
patients and in animal models of depression (Stockmeier et al., 2004; Dranovsky and Hen, 
2006), and is a key region for the integration of emotional and cognitive domains, both of 
which are affected in depression (Femenía et al., 2012). Several evidences suggest that the 
effect of monoaminergic antidepressants is mediated by the modulation of glutamatergic 
plasticity (Sanacora et al., 2012). Histamine H3R antagonists can regulate the release of 
several neurotransmitters and have displayed both antidepressant and pro-cognitive effects in 
animal experiments (Lamberti et al., 1998; Pérez-García et al., 1999; Esbenshade et al., 
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2006). We aim to study the effect of the H3R antagonist clobenpropit in the FSL rat. The 
focus of the investigation will be on the antidepressant properties of clobenpropit tested by 
the forced swim test, and the involvement of the hippocampus. We will explore the ability of 
clobenpropit to revert biochemical and glutamatergic alterations found in the hippocampus of 
FSL rats, and will identify the targets of clobenpropit's modulation. 
In FSL rats, clobenpropit acutely reduced the immobility time in the forced swim test, both 
after systemic and after hippocampal local administrations, indicating an antidepressant-like 
effect. Moreover, it improved memory performances in the passive avoidance and novel 
object recognition tests, with no alteration of the locomotor activity. FSL rats displayed 
anxiety-like behaviours in the novelty suppressed feeding, social interaction, and light/dark 
box tests, which were only minimally affected by the administration of clobenpropit. 
Therefore, clobenpropit's effects seem to be limited to cognitive and some emotional aspects, 
i.e., increased learning of a passive avoidance response to stress and reduced immobility time 
in the forced swim test, but no effect on anxiety-like behaviours. Notably, the action of 
clobenpropit in the hippocampus (by bilateral hippocampal injections) was sufficient for the 
antidepressant-like effect. Hippocampal protein levels after systemic injection of clobenpropit 
were measured by western blot. In the hippocampus, the levels of GLAST, which are reduced 
in FSL rats, were not affected by clobenpropit. GLAST reduction has been linked to 
increased excitatory inputs onto CA1 pyramidal neurons in FSL rats (Gomez-Galan et al., 
2013). Since clobenpropit exerted an effect in the forced swim test also when locally 
administered in the hippocampus, we tested whether direct application of clobenpropit on 
hippocampal slices could reduce the excitatory inputs. In agreement with the absence of 
effect on GLAST levels, clobenpropit did not change the frequency of excitatory postsynaptic 
currents measured by whole-cell patch clamp in FSL hippocampal slices. Systemic 
clobenpropit reverted the low levels of the GluN2A subunit of the NMDA receptor, with no 
changes of the other NMDA- and AMPA- receptor subunits. The GluN2A subunit mostly 
characterizes synaptic NMDA receptors and is crucial for LTP (Bartlett et al., 2007; Papouin 
et al., 2012). Since the FSL rat has impaired hippocampal LTP at CA3-CA1 connections 
(Gomez-Galan et al., 2013), we measured the effect of clobenpropit (applied on hippocampal 
slices) on LTP by recording CA1 field excitatory postsynaptic potentials evoked by Schaffer 
collateral stimulation. In accordance to the increase of the GluN2A subunit, clobenpropit 
enhanced the LTP. Both the LTP enhancement in slice and the antidepressant effect of 
clobenpropit in the forced swim test were prevented by the co-administration of the H1R and 
H2R antagonists. We hypothesise that the effect of clobenpropit could be mediated by 
disinhibition of histamine release, and consequent activation of postsynaptic H1 and H2 
receptors (Figure 2). The block of either the H1 or H2 receptor in the hippocampus did not 
increase the immobility in clobenpropit-treated rats. This indicates that the activation of either 
H1 or H2 receptor in the hippocampus was sufficient to mediate the antidepressant effect of 
clobenpropit. 
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Figure 2: schematic drawing of the glutamatergic synapse reached by the 
histaminergic terminal. In the presynaptic side, big circles containing small 
circles represent vesicles and neurotransmitter molecules, respectively. In the 
postsynaptic side, the dashed lines represent intracellular signalling pathways 
converging on the postsynaptic AMPA- and NMDA- receptors.    
 
Implications 
So far, the action of antipsychotics and antidepressant drugs on histamine receptors has been 
considered mainly in regard to the origin of their side-effects (as for sedation and weight gain 
induced by the H1R antagonism of olanzapine and tricyclic antidepressants) (Stahl, 2013). 
The H3R antagonism and inverse agonism have been explored for their potential therapeutic 
effects in Alzheimer disease, narcolepsy, schizophrenia, obesity, and neuropathic pain 
(Tiligada et al., 2011). Our results, in agreement with previous studies, encourage further 
investigation of the H3R-mediated modulation to exert antidepressant effects. Future 
experimentation should consider the use of the H3R antagonists in validated animal models 
of depression and focus on the long-term effects of the drug after chronic and acute 
clobenpropit administrations. An advantage of the H3R antagonists in depression may derive 
from their pro-cognitive properties. Depression includes cognitive symptoms (Austin et al., 
2001), and many antidepressant drugs produce cognitive side-effects (Fava et al., 2006). The 
H3R antagonists may be explored in augmentation of classical antidepressants, in order to 
obtain a synergistic effect on neurotransmitter release and neuronal plasticity, to potentiate 
the effect on mood, reduce the drug doses and increase tolerability. A possible approach is the 
synthesis of molecules that contain active fragments of H3R antagonists and reuptake 
inhibitor antidepressants (Sander et al., 2008). Unfortunately, some issues make the H3 
receptor a difficult pharmacological target. The drug affinity of H3R antagonists shows 
species-related differences, which may explain the differences in the drug effect in rat versus 
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humans. The gene coding for the H3 receptor has many splice variants that result in a large 
number of receptor isoforms with different distributions and pharmacological properties. 
Despite the progresses of the H3R pharmacology and the promising results of the H3R 
antagonists in clinical and preclinical studies, the contribution of specific isoforms of the 
receptor in the action of the H3R antagonists is largely unknown (Esbenshade et al., 2006; 
Sander et al., 2008). Moreover, the H3 receptor has constitutive activity. As a consequence, 
inverse agonists and antagonists at the H3 receptors may have different effects depending 
from the surrounding levels of endogenous histamine. The inverse agonist and the antagonist 
would produce the same effect in the presence of endogenous histamine, for instance they 
will disinhibit neurotransmitter release. Instead, in the absence of histamine, only the inverse 
agonist would be able to exert an effect (Moreno-Delgado et al., 2006). Hence the effect of 
the H3R antagonists may be strongly dependent from the histaminergic tone, and therefore 
from the actual mental state. In conclusion, the use of H3R antagonists in clinic and animal 
research represents a difficult issue due to its species-specific pharmacology, presence of 
different H3R isoforms with different pharmacological properties, and the receptor 
constitutive activity. However, the H3R modulation is not the only target to explore for a 
therapeutic perspective. Our results indicated that clobenpropit's effect was mediated by the 
activation of the H1 and H2 receptors. In a previous study, the antidepressant effect of the H1 
receptor activation and increased endogenous histamine was evidenced (Lamberti et al., 
1998). In the paper III, we will illustrate how H1 and H2 receptors differentially modulate 
glutamatergic synaptic strength in the hippocampus. These data encourage the exploration of 
strategies to modulate the histaminergic transmission in order to promote neuronal plasticity 
for a therapeutic effect.  
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CHAPTER 3 
 
HISTAMINE RECEPTOR SIGNALS  
Although the hippocampus receives moderate histaminergic innervations (Panula et al., 
1989), hippocampal neurons are highly responsive to histamine (Haas et al., 2008). We will 
discuss the intracellular signalling downstream of the H1 and H2 receptors and relevant for 
the modulation of neuronal properties.  
 
H1 receptors 
The H1 receptor is coupled to a Gq-protein and activates an intracellular pathway mediated 
by phospholipase C (PLC) and phosphokinase C (PKC). The PLC signalling induces 
mobilization of calcium from intracellular storages (Haas et al., 2008). In many neuronal 
cells, H1R activation leads to depolarization by block of leak potassium conductance (Reiner 
and Kamondi, 1994). Instead, in the hippocampal pyramidal neurons H1 receptors can 
hyperpolarize the membrane potential by the opening of calcium-activated potassium (KCa) 
channels, causing a consequent decrease of neuronal excitability (Selbach et al., 1997; 
Weiger et al., 1997). This effect on neuronal excitability may explain how H1R antagonists 
are epileptogenic (Yokoyama and Iinuma, 1996). Moreover, H1 receptors can target neuronal 
electrical properties by PKC-mediated facilitation of voltage-gated calcium channels and of 
sodium/calcium exchanger (Haas et al., 2008). The H1 receptor increases NMDAR-mediated 
currents by reducing the magnesium block (Payne and Neuman, 1997), likely through PKC 
phosphorylation (Chen and Huang, 1992). The H1 receptor is also able to trigger the 
production of arachidonic acid by PLA2 (Leurs et al., 1994), and of nitric oxide by calcium-
dependent nitric oxide synthase (Yang and Hatton, 2002), which can potentially act as 
retrograde messengers that modulate synaptic transmission. The H1 receptor activation in the 
hypothalamus in vivo increases noradrenaline release (Bealer, 1993), suggesting that H1 
receptors may either be localized presynaptically or stimulate the release of transmitters that 
in turn regulate the presynaptic release of noradrenaline.  
 
H2 receptors 
The H2 receptor is coupled to a Gs-protein and activates an intracellular pathway mediated 
by cAMP and phosphokinase A (PKA) (Haas et al., 2008). H2R activation inhibits KCa 
channels responsible for afterhyperpolarization, thus blocking the accommodation of 
neuronal firing, an effect mediated by PKA-mediated phosphorylation (Haas and Konnerth, 
1983). The H2 receptor also induces a depolarizing current (Ih) by shifting the activation 
threshold of the hyperpolarization-activated cation channel (McCormick and Williamson, 
1991). Therefore, the major effect of the H2 receptor is the depolarization of pyramidal 
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neurons and the increase in firing. However, early studies have pointed out that histamine, in 
several brain areas, reduces neuronal excitability when locally administered, likely by 
activation of H2 receptors on inhibitory interneurons (Haas and Greene, 1986; Brown et al., 
2001). A presynaptic localization of the H2 receptor has not been demonstrated, however 
some biochemical studies have reported that the H2 receptor can increase noradrenaline 
release from membrane homogenates (Timm et al., 1998), and H2 receptors may be localized 
on striatonigral endings (Vizuete et al., 1997). The intracellular signalling of the H2 receptor 
is very similar to the dopamine D1-like and the adrenergic β1 receptors, which are localized 
on presynaptic terminals (as well as postsynaptically) and mediate neurotransmitter release 
(Brown et al., 2001). 
 
HISTAMINERGIC MODULATION OF SYNAPTIC PLASTICITY 
The intracellular signalling pathways activated by histamine (PKC, intracellular calcium 
signal, cAMP/PKA pathway) are involved in neuronal plasticity. Histamine produces a long-
lasting increase of neuronal excitability in hippocampal pyramidal neurons, with an increase 
of cell firing (Selbach et al., 1997) by H2 receptor activation. However, the H1 receptor 
strongly potentiates the effect of the H2 receptor, likely by activation of intracellular calcium 
signalling and calcium/calmodulin subunit that potentiates the H2R-activated adenylate 
cyclase (Garbarg and Schwartz, 1988; Bakker et al., 2004). Another coincidence detector for 
synaptic plasticity is the NMDA receptor. The NMDA receptor plays a major role in several 
forms of synaptic plasticity, by increasing intracellular calcium levels and activating calcium-
dependent kinases (Luscher and Malenka, 2012). The H1 receptor both increases NMDAR-
mediated currents by reducing the magnesium block (Payne and Neuman, 1997) (likely 
through PKC phosphorylation (Chen and Huang, 1992)) and increases intracellular calcium 
levels, playing a potential role for long-term plasticity. The H2 receptor activates the 
cAMP/PKA pathway (moreover synergistically amplified by the H1 receptor) that can alone 
induce NMDAR-independent synaptic potentiation in hippocampal slices (Frey et al., 1993). 
Potentiation of the NMDA receptor can also occur by direct action of histamine on the 
polyamine-binding site of NMDA receptors (Bekkers, 1993; Brown et al., 1995b) (or, as 
recently suggested, by a different binding site (Burban et al., 2010)). However, this action is 
restricted to GluN1/N2B-containing receptors (Williams, 1994) and occurs only in conditions 
of low tissue pH (7.2), like during high firing frequency, epileptic attacks, ischemia, 
hypoglycemia, and tetanic stimulation in slice (Brown et al., 1995a; Saybasili et al., 1995; 
Yanovsky et al., 1995). AMPA receptor (AMPAR) trafficking regulates receptor expression 
on the synaptic membranes. It is involved in synaptic plasticity processes regulated by 
calcium/calmodulin kinases and PKA (Esteban et al., 2003; Luscher and Malenka, 2012). 
Histamine increases the synaptic insertion of particular AMPAR subunits (GluR2L and 
GluR1) (Qin et al., 2005). AMPAR subunits are differentially recruited during activity-
dependent plasticity: GluR2-lacking AMPA receptors (formed by GluR1 homodimers) 
underlie the short-term changes of plasticity, whereas the GluR2-containing AMPA receptors 
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increase in the long-term (Isaac et al., 2007). Notably, histamine-triggered insertion of the 
GluR2L and GluR1 subunits at synaptic level is mediated by two different pathways: the Ras-
MEK-ERK signal and the Ras-Pi3K-PKB signals, the former required for GluR2L synaptic 
trafficking and both required for GluR1 (Qin et al., 2005). Therefore, histamine may shape 
the progression of short- and long-term plasticity. The contribution of the specific histamine 
receptor subtypes has never been explored. 
In conclusion, the main effect of histamine concerns the neuromodulation of neuronal 
properties and plasticity, by facilitation or prevention of activity-dependent plasticity 
processes. Moreover, histamine affects synaptic glutamate receptors and mechanisms of 
vesicle release, by which it is likely to modulate synaptic transmission. 
 
HISTAMINE H1 AND H2 RECEPTOR-MEDIATED MODULATION OF 
GLUTAMATERGIC SYNAPTIC STRENGTH IN THE HIPPOCAMPUS - (PAPER 
III)      
Summary 
Synaptic strength can be defined as the product of vesicle release probability, number of 
release sites, and quantal size (i.e., the postsynaptic response to presynaptic neurotransmitter 
release of a single vesicle) (Kerchner and Nicoll, 2008). Changes of synaptic strength occur 
in response to synaptic activity perturbations (for instance, adaptation to synaptic inactivity 
(Turrigiano et al., 1998) or activity-driven long-term potentiation (Frey and Morris, 1997)). 
Miniature excitatory postsynaptic currents (mEPSC, or minis) are generated by the 
spontaneous release of individual synaptic vesicles and provide a good measure of synaptic 
strength (Kerchner and Nicoll, 2008). Neuromodulators, such as dopamine, have been found 
to change mEPSCs. In hippocampal cultured neurons, the D1 receptor activation increases 
mEPSC frequency, likely by the recruitment of AMPA GluR1 subunits in silent synapses 
(Smith et al., 2005). As previously described, histamine can modulate activity-dependent 
plasticity. Our aim is to study the neuromodulatory effect of histamine on hippocampal 
synaptic strength. We recorded mEPSCs by whole-cell patch clamp of CA1 pyramidal 
neurons in slices from Sprague Dawley rats. 
We found that the activation of the H1 receptor reduced the frequency, but not amplitude, of 
mEPSCs recorded from CA1 pyramidal neurons. Instead, the H2R agonist did not change 
mEPSC frequency or amplitude. The selective change in frequency with no effect on the 
amplitude of mEPSCs suggests two possible mechanisms of modulation (Kerchner and 
Nicoll, 2008): reduction of presynaptic vesicle release probability; internalization of 
postsynaptic AMPA receptors with consequent silencing of the synapses. The paired-pulse 
facilitation at CA3-CA1 synaptic connections (which measures the release probability of 
action-potential evoked transmission) was not affected by the H1R agonist. Although this 
suggests to exclude a presynaptic modulation of mEPSC frequency, the H1 receptor may 
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selectively modulate the probability of release of spontaneous, but not evoked, glutamatergic 
transmission. For instance, spontaneous mEPSC frequency can be selectively modulated by 
the activation of apolipoprotein E receptor2 (ApoER2) signalling and release of calcium from 
presynaptic intracellular storages, with no effect on evoked transmission (Bal et al., 2013). 
Similarly to the ApoER2, the H1 receptor leads to an increase of intracellular calcium via the 
PLC/IP3 cascade, possibly explaining the presynaptic H1R modulation of spontaneous 
vesicle release. Notably, it has been found that the H1 receptor modulates the vesicle release 
machinery. Indeed, in chromaffin cells, H1R activation increases the neurotransmitter release 
by PLC activation, priming of the synaptic vesicles, and increase of the readily releasable 
pool (Bauer et al., 2007). We should note that the mechanisms described lead to an increase 
of vesicle release, while we observed that the H1R agonist decreased mEPSC frequency, 
suggesting a reduction of release probability. The H1 receptor is known to be localized on the 
postsynaptic side, however some data suggest that histamine can affect presynaptic release of 
noradrenaline in the hypothalamus by H1 receptors (Bealer, 1993). To date, the 
demonstration of a presynaptic localization of the H1 receptor is lacking. Alternatively, 
postsynaptic H1 receptors may trigger a retrograde signal mediated by endocannabinoids 
(Leurs et al., 1994) that would reduce presynaptic release probability. However, preliminary 
data from our lab seem to exclude that the effect of the H1R agonist could be blocked by the 
endocannabinoid CB1 receptor antagonist AM-251. The H1R-mediated reduction of mEPSC 
frequency may also be explained by internalization of postsynaptic AMPA receptors and 
silencing of synapses. AMPAR trafficking is likely to be involved in the modulation of 
mEPSCs by dopamine D1 receptors (Smith et al., 2005). Currently, we are working to test the 
hypothesis that the change of mEPSC frequency has a postsynaptic origin: in this case, the 
block of postsynaptic intracellular signalling triggered by the H1 receptor (for instance, by 
using a PKC inhibitor in the patch pipette) would prevent the reduction of mEPSC frequency 
induced by the H1R agonist. The AMPAR internalization will be tested by isolating the 
postsynaptic density from tissue exposed to the H1R agonist: we hypothesise that the H1R 
agonist will induce a reduction of the AMPAR levels in the postsynaptic density fraction.  
 
Implications 
The H1 receptor, but not the H2 receptor, can affect glutamatergic synaptic strength. The 
differential modulatory effect of the histamine receptor subtypes has been already observed 
on neuronal properties and activity-dependent plasticity. As previously described, the main 
effect of histamine involves neuronal firing properties (Haas et al., 2008). Here we evidenced 
that the H1 receptor can modulate glutamatergic synaptic strength with no clear changes of 
evoked transmission, potentially predisposing the synapse to activity-dependent plasticity. 
This phenomenon is called metaplasticity (MacDonald et al., 2007). An example of 
metaplasticity is the facilitation of the LTP observed by the H3R antagonist clobenpropit 
(paper II: Femenia et al., 2015) or by histamine (Brown et al., 1995b). Changes of 
spontaneous neurotransmission (like the mEPSC modulation by the H1 receptor) may be an 
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important mechanism of metaplasticity. NMDAR-mediated minis suppress local dendritic 
protein synthesis and participate to mechanisms of synaptic homeostasis (Sutton et al., 2006; 
Sutton et al., 2007). Those mechanisms are also involved in the fast antidepressant response 
of ketamine, by disinhibition of dendritic protein synthesis of BDNF in the hippocampus 
(Autry et al., 2011). We show that the H1 receptor reduces mEPSC frequency in the 
hippocampus, but it has not been explored whether the H1R-mediated modulation is relevant 
for synaptic homeostasis in the long term. However, testing the antidepressant properties of 
the H3R antagonists has indicated that hippocampal H1 receptors mediate the antidepressant 
response in the FSL rats (paper II: Femenia et al., 2015). Moreover, the H1 receptor agonist 
induced an antidepressant response in mice (Lamberti et al., 1998). The histaminergic 
modulation of homeostatic plasticity may represent a novel frontier to interfere with 
mechanisms relevant for a therapeutic perspective. 
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CONCLUSIONS 
 
The identification of altered explorative strategies and reactive coping style in the FSL rat 
contributes to the understanding of the FSL behavioural profile and supports its face validity 
as model of depression. Differences in explorative strategies and coping styles may explain 
the behavioural variability in animal testing and drug response, and may constitute the basis 
to understand the resilience/vulnerability to stress.  
The high emotional reactivity and reactive coping style of the FSL rat are characterized by 
risk-assessment behaviours and avoidance/immobility. This exploratory profile matches with 
the anxiety-like behaviours (increased latency to reach the food, preference for the dark 
compartment, less social interaction) that we observed in traditional tests (i.e., novelty 
suppressed feeding, light/dark box, and social interaction tests). However, in the MCSF test, 
FSL rats performed risk taking to the same extent as SD rats (or even more when re-exposed 
to the MCSF arena). This suggests that the setting and duration of the test may allow the 
animal to adopt adequate explorative strategies and reach the level of SD rats' performance.  
To our knowledge, the MCSF, novel cage and home cage change tests (used for the 
evaluation of explorative strategies and coping styles) have not been explored with regard to 
their predictive validity for drug antidepressant effects. However, the immobility rate in the 
forced swim test could be considered as an expression of coping style, suggesting that the 
assessment of coping styles may be useful to evaluate antidepressant properties. Given the 
positive results of clobenpropit in the forced swim test, it may be worthwhile to study the 
effects of both clobenpropit and classical antidepressants on the performances measured in 
the MCSF and novel cage tests.  
Clobenpropit's antidepressant properties and its impact on plasticity should be followed up by 
studies investigating its long-term effects. We provide evidence that the antidepressant action 
is mediated by activation of hippocampal H1 and H2 receptors, likely through an increase of 
histamine release. This mechanism is likely to trigger neuronal plasticity in FSL rats, and, 
accordingly, we found an increase in GluN2A expression and enhancement of hippocampal 
plasticity induced by clobenpropit. However, we do not know whether the effect of 
clobenpropit is dependent on new protein synthesis. It is relevant to note that the crucial step 
for clobenpropit's antidepressant mechanism seems to be the activation of the H1 and H2 
receptors, but not the H3R antagonism by itself. We showed that the H1 receptor is involved 
in the modulation of synaptic strength in Sprague Dawley rats; potentially a similar 
modulation is maintained in FSL rats. The mechanisms and relevance of such modulation are 
still unclear. The H1 receptor may affect synaptic homeostasis, which could represent a new 
aspect of the histaminergic neuromodulation.  
  25 
ACKNOWLEDGEMENTS 
The PhD has driven me through new experiences, in many ways. People around me have 
supported, guided, inspired, and/or just carefully listened to the changes occurring in my life, 
while looking after me from close by or far away. Those people I want to thank: 
Mia, whom I enjoyed working with: our different professional and personal attitudes have 
been for me an inspiration to improve, to the point that I can now overcome better my natural 
scientific cautiousness, explore with enthusiasm the novelty, and be in time to the meetings. 
And thanks for being always ready for answering questions and discussions. 
Erika and Sarah, for your encouragement and the great exchange of scientific ideas. I am 
totally grateful you embarked with me in a project despite of my demanding time schedule. 
Gilberto, Abdel and Gilad, for inspiration and help. 
Teresa, for your support and team-work besides of your personal kindness. Marta, who taught 
me that, to solve a problem, I should do both everything that makes sense and what does not, 
because at some point I will do something that solves the problem. Dimitri, whom I have 
great admiration for. 
The kids Giorgia, Maya, Emeline and QP, who make me happy. 
Laura, unlimited source of inspiration and joy in many ways, who fostered my hunger for 
reading and made me lose my mind in Dahl's novels. Richard, who is my Mr. Jeeves popped 
out from a Wodehouse's tale. 
Stephanos, for the nice adventures and his constant scientific support. 
Niklas, Linda, Karin, Susanne, Helena, and the others, for their smiles and precious help. 
Rosaria, for you nowhere is too far from me. 
Ilary, who enjoys making me feel a wise older brother. 
Martijn, a good scientist and a good heart. 
Catlin and Giada, who are my Genius of the Lamp with phenomenal cosmic power, 
constantly on my side in the personal and professional life. 
Friends like Lovisa, Paul, Johan, Yvonne, Arash, Susanne, Pawel, Julio, Emy, Carmelo, 
Vanessa, Laura and many others met during these years. 
Veronica, my parents, my sister, who give me constant support even when they do not agree 
with my choices.   
Thank you all! 

  27 
REFERENCES 
Abildgaard, A., Solskov, L., Volke, V., Harvey, B.H., Lund, S., and Wegener, G. (2011). A 
high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) 
rat, a genetic model of depression. Psychoneuroendocrinology 36, 623-633. doi: 
10.1016/j.psyneuen.2010.09.004. 
Allyson, J., Bi, X., Baudry, M., and Massicotte, G. (2012). Maintenance of synaptic stability 
requires calcium-independent phospholipase A(2) activity. Neural Plast 2012, 
569149. doi: 10.1155/2012/569149. 
Apa (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American 
Psychiatric Association. United States. 
Austin, M.P., Mitchell, P., and Goodwin, G.M. (2001). Cognitive deficits in depression: 
possible implications for functional neuropathology. Br J Psychiatry 178, 200-206. 
Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., Kavalali, E.T., and 
Monteggia, L.M. (2011). NMDA receptor blockade at rest triggers rapid behavioural 
antidepressant responses. Nature 475, 91-95. doi: 10.1038/nature10130. 
Bahi, A., Schwed, J.S., Walter, M., Stark, H., and Sadek, B. (2014). Anxiolytic and 
antidepressant-like activities of the novel and potent non-imidazole histamine H3 
receptor antagonist ST-1283. Drug Des Devel Ther 8, 627-637. doi: 
10.2147/DDDT.S63088. 
Bakker, R.A., Casarosa, P., Timmerman, H., Smit, M.J., and Leurs, R. (2004). Constitutively 
active Gq/11-coupled receptors enable signaling by co-expressed G(i/o)-coupled 
receptors. J Biol Chem 279, 5152-5161. doi: 10.1074/jbc.M309200200 
Bal, M., Leitz, J., Reese, A.L., Ramirez, D.M., Durakoglugil, M., Herz, J., Monteggia, L.M., 
and Kavalali, E.T. (2013). Reelin mobilizes a VAMP7-dependent synaptic vesicle 
pool and selectively augments spontaneous neurotransmission. Neuron 80, 934-946. 
doi: 10.1016/j.neuron.2013.08.024. 
Bartlett, T.E., Bannister, N.J., Collett, V.J., Dargan, S.L., Massey, P.V., Bortolotto, Z.A., 
Fitzjohn, S.M., Bashir, Z.I., Collingridge, G.L., and Lodge, D. (2007). Differential 
roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 
region of two-week old rat hippocampus. Neuropharmacology 52, 60-70. doi: 
http://dx.doi.org/10.1016/j.neuropharm.2006.07.013. 
Bauer, C.S., Woolley, R.J., Teschemacher, A.G., and Seward, E.P. (2007). Potentiation of 
exocytosis by phospholipase C-coupled G-protein-coupled receptors requires the 
priming protein Munc13-1. J Neurosci 27, 212-219. doi: 10.1523/JNEUROSCI.4201-
06.2007. 
Baumeister, A.A., Hawkins, M.F., and Uzelac, S.M. (2003). The myth of reserpine-induced 
depression: role in the historical development of the monoamine hypothesis. J Hist 
Neurosci 12, 207-220. doi: 10.1076/jhin.12.2.207.15535. 
Bealer, S.L. (1993). Histamine releases norepinephrine in the paraventricular nucleus/anterior 
hypothalamus of the conscious rat. J Pharmacol Exp Ther 264, 734-738. 
Bekkers, J.M. (1993). Enhancement by histamine of NMDA-mediated synaptic transmission 
in the hippocampus. Science 261, 104-106. 
 28 
Benus, R.F., Bohus, B., Koolhaas, J.M., and Van Oortmerssen, G.A. (1991). Heritable 
variation for aggression as a reflection of individual coping strategies. Experientia 47, 
1008-1019. 
Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., and 
Krystal, J.H. (2000). Antidepressant effects of ketamine in depressed patients. Biol 
Psychiatry 47, 351-354. doi: S0006-3223(99)00230-9 [pii]. 
Berton, O., and Nestler, E.J. (2006). New approaches to antidepressant drug discovery: 
beyond monoamines. Nat Rev Neurosci 7, 137-151. doi: 10.1038/nrn1846. 
Bickerdike, M.J., Marsden, C.A., Dourish, C.T., and Fletcher, A. (1994). The influence of 5-
hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat 
elevated zero-maze. Eur J Pharmacol 271, 403-411. 
Blanchard, D.C., and Blanchard, R.J. (1988). Ethoexperimental approaches to the biology of 
emotion. Annu Rev Psychol 39, 43-68. doi: 10.1146/annurev.ps.39.020188.000355. 
Blanchard, R.J., and Blanchard, D.C. (1989). Attack and defense in rodents as 
ethoexperimental models for the study of emotion. Prog Neuropsychopharmacol Biol 
Psychiatry 13 Suppl, S3-14. 
Bongers, G., Sallmen, T., Passani, M.B., Mariottini, C., Wendelin, D., Lozada, A., Marle, A., 
Navis, M., Blandina, P., Bakker, R.A., Panula, P., and Leurs, R. (2007). The 
Akt/GSK-3beta axis as a new signaling pathway of the histamine H(3) receptor. J 
Neurochem 103, 248-258. doi: 10.1111/j.1471-4159.2007.04752.x. 
Bremner, J.D., Vythilingam, M., Vermetten, E., Vaccarino, V., and Charney, D.S. (2004). 
Deficits in hippocampal and anterior cingulate functioning during verbal declarative 
memory encoding in midlife major depression. Am J Psychiatry 161, 637-645. 
Brown, R.E., Fedorov, N.B., Haas, H.I., and Reyman, K.G. (1995a). Histaminergic 
modulation of synaptic plasticity in area CA1 of rat hippocampal slices. 
Neuropharmacology 34, 181-190. 
Brown, R.E., Fedorov, N.B., Haas, H.L., and Reymann, K.G. (1995b). Histaminergic 
modulation of synaptic plasticity in area CA1 of rat hippocampal slices. 
Neuropharmacology 34, 181-190. doi: 002839089400138I [pii]. 
Brown, R.E., Stevens, D.R., and Haas, H.L. (2001). The physiology of brain histamine. Prog 
Neurobiol 63, 637-672. doi: S0301008200000393 [pii]. 
Burban, A., Faucard, R., Armand, V., Bayard, C., Vorobjev, V., and Arrang, J.M. (2010). 
Histamine potentiates N-methyl-D-aspartate receptors by interacting with an allosteric 
site distinct from the polyamine binding site. J Pharmacol Exp Ther 332, 912-921. 
doi: 10.1124/jpet.109.158543. 
Burn, C.C., Peters, A., Day, M.J., and Mason, G.J. (2006). Long-term effects of cage-
cleaning frequency and bedding type on laboratory rat health, welfare, and 
handleability: a cross-laboratory study. Lab Anim 40, 353-370. doi: 
10.1258/002367706778476460. 
Cairns, K.E., Yap, M.B., Pilkington, P.D., and Jorm, A.F. (2014). Risk and protective factors 
for depression that adolescents can modify: a systematic review and meta-analysis of 
longitudinal studies. J Affect Disord 169, 61-75. doi: 10.1016/j.jad.2014.08.006. 
  29 
Campbell, S., Marriott, M., Nahmias, C., and Macqueen, G.M. (2004). Lower hippocampal 
volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 161, 
598-607. 
Celikel, F.C., Kose, S., Cumurcu, B.E., Erkorkmaz, U., Sayar, K., Borckardt, J.J., and 
Cloninger, C.R. (2009). Cloninger's temperament and character dimensions of 
personality in patients with major depressive disorder. Compr Psychiatry 50, 556-
561. doi: 10.1016/j.comppsych.2008.11.012. 
Chen, L., and Huang, L.Y. (1992). Protein kinase C reduces Mg2+ block of NMDA-receptor 
channels as a mechanism of modulation. Nature 356, 521-523. doi: 
10.1038/356521a0. 
Cloninger, C.R., Svrakic, D.M., and Przybeck, T.R. (1993). A psychobiological model of 
temperament and character. Arch Gen Psychiatry 50, 975-990. 
Connelly, W.M., Shenton, F.C., Lethbridge, N., Leurs, R., Waldvogel, H.J., Faull, R.L.M., 
Lees, G., and Chazot, P.L. (2009). The histamine H(4) receptor is functionally 
expressed on neurons in the mammalian CNS. British Journal of Pharmacology 157, 
55-63. doi: 10.1111/j.1476-5381.2009.00227.x. 
Coppens, C.M., De Boer, S.F., Steimer, T., and Koolhaas, J.M. (2013). Correlated behavioral 
traits in rats of the Roman selection lines. Behav Genet 43, 220-226. doi: 
10.1007/s10519-013-9588-8. 
Craig, J.V. (1986). Measuring social behavior: social dominance. J Anim Sci 62, 1120-1129. 
Cuthbert, B.N., and Insel, T.R. (2013). Toward the future of psychiatric diagnosis: the seven 
pillars of RDoC. BMC Med 11, 126. doi: 10.1186/1741-7015-11-126. 
Deckersbach, T., Dougherty, D.D., Savage, C., Mcmurrich, S., Fischman, A.J., Nierenberg, 
A., Sachs, G., and Rauch, S.L. (2006). Impaired recruitment of the dorsolateral 
prefrontal cortex and hippocampus during encoding in bipolar disorder. Biol 
Psychiatry 59, 138-146. doi: 10.1016/j.biopsych.2005.06.030. 
Douglas, R.J., and Martin, K.A. (2007). Mapping the matrix: the ways of neocortex. Neuron 
56, 226-238. doi: 10.1016/j.neuron.2007.10.017. 
Drai, D., Kafkafi, N., Benjamini, Y., Elmer, G., and Golani, I. (2001). Rats and mice share 
common ethologically relevant parameters of exploratory behavior. Behav Brain Res 
125, 133-140. doi: S0166-4328(01)00290-X [pii]. 
Dranovsky, A., and Hen, R. (2006). Hippocampal neurogenesis: regulation by stress and 
antidepressants. Biol Psychiatry 59, 1136-1143. doi: 10.1016/j.biopsych.2006.03.082. 
Dudek, B.C., Adams, N., Boice, R., and Abbott, M.E. (1983). Genetic influences on digging 
behaviors in mice (Mus musculus) in laboratory and seminatural settings. J Comp 
Psychol 97, 249-259. 
Duman, C.H. (2010). "Chapter One - Models of Depression," in Vitamins & Hormones, ed. 
L. Gerald. Academic Press), 1-21. 
Duman, R.S., Li, N., Liu, R.J., Duric, V., and Aghajanian, G. (2012). Signaling pathways 
underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62, 35-
41. doi: 10.1016/j.neuropharm.2011.08.044. 
Eilam, D., and Golani, I. (1989). Home base behavior of rats (Rattus norvegicus) exploring a 
novel environment. Behav Brain Res 34, 199-211. 
 30 
Eriksson, T.M., Delagrange, P., Spedding, M., Popoli, M., Mathe, A.A., Ogren, S.O., and 
Svenningsson, P. (2012). Emotional memory impairments in a genetic rat model of 
depression: involvement of 5-HT/MEK/Arc signaling in restoration. Mol Psychiatry 
17, 173-184. doi: 10.1038/mp.2010.131. 
Esbenshade, T.A., Browman, K.E., Bitner, R.S., Strakhova, M., Cowart, M.D., and Brioni, 
J.D. (2008). The histamine H3 receptor: an attractive target for the treatment of 
cognitive disorders. Br J Pharmacol 154, 1166-1181. doi: 10.1038/bjp.2008.147. 
Esbenshade, T.A., Fox, G.B., and Cowart, M.D. (2006). Histamine H3 receptor antagonists: 
preclinical promise for treating obesity and cognitive disorders. Mol Interv 6, 77-88, 
59. doi: 10.1124/mi.6.2.5. 
Esteban, J.A., Shi, S.H., Wilson, C., Nuriya, M., Huganir, R.L., and Malinow, R. (2003). 
PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking 
underlying plasticity. Nat Neurosci 6, 136-143. doi: 10.1038/nn997 
Fava, M., Graves, L.M., Benazzi, F., Scalia, M.J., Iosifescu, D.V., Alpert, J.E., and 
Papakostas, G.I. (2006). A cross-sectional study of the prevalence of cognitive and 
physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 67, 
1754-1759. 
Femenía, T., Gómez-Galán, M., Lindskog, M., and Magara, S. (2012). Dysfunctional 
hippocampal activity affects emotion and cognition in mood disorders. Brain 
Research 1476, 58-70. doi: http://dx.doi.org/10.1016/j.brainres.2012.03.053. 
Femenia, T., Magara, S., Dupont, C.M., and Lindskog, M. (2015). Hippocampal-Dependent 
Antidepressant Action of the H3 Receptor Antagonist Clobenpropit in a Rat Model of 
Depression. Int J Neuropsychopharmacol. doi: 10.1093/ijnp/pyv032. 
Fernandez-Espejo, E., and Mir, D. (1990). Behavioral study in rats of paired accumbens-
lesioned residents and intact intruders. Physiol Behav 47, 941-947. doi: 0031-
9384(90)90022-V [pii]. 
Frey, U., Huang, Y.Y., and Kandel, E.R. (1993). Effects of cAMP simulate a late stage of 
LTP in hippocampal CA1 neurons. Science 260, 1661-1664. 
Frey, U., and Morris, R.G. (1997). Synaptic tagging and long-term potentiation. Nature 385, 
533-536. doi: 10.1038/385533a0. 
Gao, Z., Hurst, W.J., Czechtizky, W., Hall, D., Moindrot, N., Nagorny, R., Pichat, P., 
Stefany, D., Hendrix, J.A., and George, P.G. (2013). Identification and profiling of 
3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-
[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the 
treatment of depression. Bioorg Med Chem Lett 23, 6269-6273. doi: 
10.1016/j.bmcl.2013.09.081. 
Garbarg, M., and Schwartz, J.C. (1988). Synergism between histamine H1- and H2-receptors 
in the cAMP response in guinea pig brain slices: effects of phorbol esters and 
calcium. Mol Pharmacol 33, 38-43. 
Giovannini, M.G., Efoudebe, M., Passani, M.B., Baldi, E., Bucherelli, C., Giachi, F., 
Corradetti, R., and Blandina, P. (2003). Improvement in Fear Memory by Histamine-
Elicited ERK2 Activation in Hippocampal CA3 Cells. The Journal of Neuroscience 
23, 9016-9023. 
  31 
Gomez-Galan, M., De Bundel, D., Van Eeckhaut, A., Smolders, I., and Lindskog, M. (2013). 
Dysfunctional astrocytic regulation of glutamate transmission in a rat model of 
depression. Mol Psychiatry 18, 582-594. doi: 10.1038/mp.2012.10. 
Gould, N.F., Holmes, M.K., Fantie, B.D., Luckenbaugh, D.A., Pine, D.S., Gould, T.D., 
Burgess, N., Manji, H.K., and Zarate, C.A., Jr. (2007). Performance on a virtual 
reality spatial memory navigation task in depressed patients. Am J Psychiatry 164, 
516-519. doi: 10.1176/appi.ajp.164.3.516. 
Haas, H.L., and Greene, R.W. (1986). Effects of histamine on hippocampal pyramidal cells 
of the rat in vitro. Exp Brain Res 62, 123-130. 
Haas, H.L., and Konnerth, A. (1983). Histamine and noradrenaline decrease calcium-
activated potassium conductance in hippocampal pyramidal cells. Nature 302, 432-
434. 
Haas, H.L., Sergeeva, O.A., and Selbach, O. (2008). Histamine in the nervous system. 
Physiol Rev 88, 1183-1241. doi: 10.1152/physrev.00043.2007. 
Hansenne, M., Reggers, J., Pinto, E., Kjiri, K., Ajamier, A., and Ansseau, M. (1999). 
Temperament and character inventory (TCI) and depression. J Psychiatr Res 33, 31-
36. doi: S0022-3956(98)00036-3 [pii]. 
Hettema, J.M. (2008). The nosologic relationship between generalized anxiety disorder and 
major depression. Depress Anxiety 25, 300-316. doi: 10.1002/da.20491. 
Hughes, R.N. (1997). Intrinsic exploration in animals: motives and measurement. Behav 
Processes 41, 213-226. doi: S0376-6357(97)00055-7 [pii]. 
Hyman, S.E. (2007). Can neuroscience be integrated into the DSM-V? Nat Rev Neurosci 8, 
725-732. doi: 10.1038/nrn2218. 
Isaac, J.T., Ashby, M.C., and Mcbain, C.J. (2007). The role of the GluR2 subunit in AMPA 
receptor function and synaptic plasticity. Neuron 54, 859-871. doi: 
10.1016/j.neuron.2007.06.001. 
Kavalali, E.T., and Monteggia, L.M. (2015). How does ketamine elicit a rapid antidepressant 
response? Curr Opin Pharmacol 20, 35-39. doi: 10.1016/j.coph.2014.11.005. 
Kazlauckas, V., Schuh, J., Dall'igna, O.P., Pereira, G.S., Bonan, C.D., and Lara, D.R. (2005). 
Behavioral and cognitive profile of mice with high and low exploratory phenotypes. 
Behav Brain Res 162, 272-278. doi: 10.1016/j.bbr.2005.03.021. 
Kerchner, G.A., and Nicoll, R.A. (2008). Silent synapses and the emergence of a postsynaptic 
mechanism for LTP. Nat Rev Neurosci 9, 813-825. doi: 10.1038/nrn2501. 
Koolhaas, J.M. (2008). Coping style and immunity in animals: making sense of individual 
variation. Brain Behav Immun 22, 662-667. doi: 10.1016/j.bbi.2007.11.006. 
Koolhaas, J.M., De Boer, S.F., Buwalda, B., and Van Reenen, K. (2007). Individual variation 
in coping with stress: a multidimensional approach of ultimate and proximate 
mechanisms. Brain Behav Evol 70, 218-226. doi: 10.1159/000105485. 
Koolhaas, J.M., Korte, S.M., De Boer, S.F., Van Der Vegt, B.J., Van Reenen, C.G., Hopster, 
H., De Jong, I.C., Ruis, M.A., and Blokhuis, H.J. (1999). Coping styles in animals: 
current status in behavior and stress-physiology. Neurosci Biobehav Rev 23, 925-935. 
doi: S0149-7634(99)00026-3 [pii]. 
 32 
Koolhaas, J.M., Schuurman, T., and Wiepkema, P.R. (1980). The organization of 
intraspecific agonistic behaviour in the rat. Prog Neurobiol 15, 247-268. doi: 0301-
0082(80)90024-6 [pii]. 
Koolschijn, P.C., Van Haren, N.E., Lensvelt-Mulders, G.J., Hulshoff Pol, H.E., and Kahn, 
R.S. (2009). Brain volume abnormalities in major depressive disorder: a meta-
analysis of magnetic resonance imaging studies. Hum Brain Mapp 30, 3719-3735. 
doi: 10.1002/hbm.20801. 
Korte, S.M., Meijer, O.C., De Kloet, E.R., Buwalda, B., Keijser, J., Sluyter, F., Van 
Oortmerssen, G., and Bohus, B. (1996). Enhanced 5-HT1A receptor expression in 
forebrain regions of aggressive house mice. Brain Res 736, 338-343. doi: 0006-
8993(96)00723-8 [pii]. 
Lamberti, C., Ipponi, A., Bartolini, A., Schunack, W., and Malmberg-Aiello, P. (1998). 
Antidepressant-like effects of endogenous histamine and of two histamine H1 
receptor agonists in the mouse forced swim test. Br J Pharmacol 123, 1331-1336. doi: 
10.1038/sj.bjp.0701740. 
Leurs, R., Traiffort, E., Arrang, J.M., Tardivel-Lacombe, J., Ruat, M., and Schwartz, J.C. 
(1994). Guinea pig histamine H1 receptor. II. Stable expression in Chinese hamster 
ovary cells reveals the interaction with three major signal transduction pathways. J 
Neurochem 62, 519-527. 
Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., and 
Duman, R.S. (2010). mTOR-dependent synapse formation underlies the rapid 
antidepressant effects of NMDA antagonists. Science 329, 959-964. doi: 
10.1126/science.1190287. 
Luscher, C., and Malenka, R.C. (2012). NMDA receptor-dependent long-term potentiation 
and long-term depression (LTP/LTD). Cold Spring Harb Perspect Biol 4. doi: 
10.1101/cshperspect.a005710. 
Macdonald, J.F., Jackson, M.F., and Beazely, M.A. (2007). G protein-coupled receptors 
control NMDARs and metaplasticity in the hippocampus. Biochim Biophys Acta 
1768, 941-951. doi: 10.1016/j.bbamem.2006.12.006. 
Magara, S., Holst, S., Lundberg, S., Roman, E., and Lindskog, M. (2015). Altered explorative 
strategies and reactive coping style in the FSL rat model of depression. Frontiers in 
Behavioral Neuroscience 9. doi: 10.3389/fnbeh.2015.00089. 
Marques, J.M., Olsson, I.A., Ogren, S.O., and Dahlborn, K. (2008). Evaluation of exploration 
and risk assessment in pre-weaning mice using the novel cage test. Physiol Behav 93, 
139-147. doi: 10.1016/j.physbeh.2007.08.006. 
Mcclintock, S.M., Husain, M.M., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Trivedi, 
M.H., Cook, I., Morris, D., Warden, D., and Rush, A.J. (2011). Residual Symptoms in 
Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant 
Medication. Journal of Clinical Psychopharmacology 31, 180-186 
110.1097/JCP.1090b1013e31820ebd31822c. 
Mccormick, D.A., and Williamson, A. (1991). Modulation of neuronal firing mode in cat and 
guinea pig LGNd by histamine: possible cellular mechanisms of histaminergic control 
of arousal. J Neurosci 11, 3188-3199. 
  33 
Meyerson, B.J., Augustsson, H., Berg, M., and Roman, E. (2006). The Concentric Square 
Field: a multivariate test arena for analysis of explorative strategies. Behav Brain Res 
168, 100-113. doi: 10.1016/j.bbr.2005.10.020. 
Momeni, S., Sharif, M., Agren, G., and Roman, E. (2014). Individual differences in risk-
related behaviors and voluntary alcohol intake in outbred Wistar rats. Behav 
Pharmacol 25, 206-215. doi: 10.1097/FBP.0000000000000036. 
Moreno-Delgado, D., Torrent, A., Gomez-Ramirez, J., De Esch, I., Blanco, I., and Ortiz, J. 
(2006). Constitutive activity of H3 autoreceptors modulates histamine synthesis in rat 
brain through the cAMP/PKA pathway. Neuropharmacology 51, 517-523. doi: 
10.1016/j.neuropharm.2006.04.010. 
Morisset, S., Rouleau, A., Ligneau, X., Gbahou, F., Tardivel-Lacombe, J., Stark, H., 
Schunack, W., Ganellin, C.R., Schwartz, J.C., and Arrang, J.M. (2000). High 
constitutive activity of native H3 receptors regulates histamine neurons in brain. 
Nature 408, 860-864. doi: 10.1038/35048583. 
Nagase, Y., Uchiyama, M., Kaneita, Y., Li, L., Kaji, T., Takahashi, S., Konno, M., Mishima, 
K., Nishikawa, T., and Ohida, T. (2009). Coping strategies and their correlates with 
depression in the Japanese general population. Psychiatry Res 168, 57-66. doi: 
10.1016/j.psychres.2008.03.024. 
Nestler, E.J., and Hyman, S.E. (2010). Animal models of neuropsychiatric disorders. Nat 
Neurosci 13, 1161-1169. doi: 10.1038/nn.2647. 
Nimh (2008). The National Institute of Mental Health Strategic Plan. National Institute of 
Mental Health. Bethesda, MD. http://www.nimh.nih.gov/about/strategic-planning-
reports/index.shtml. 
Nosyreva, E., Szabla, K., Autry, A.E., Ryazanov, A.G., Monteggia, L.M., and Kavalali, E.T. 
(2013). Acute suppression of spontaneous neurotransmission drives synaptic 
potentiation. J Neurosci 33, 6990-7002. doi: 10.1523/JNEUROSCI.4998-12.2013. 
Orrego, F., and Villanueva, S. (1993). The chemical nature of the main central excitatory 
transmitter: a critical appraisal based upon release studies and synaptic vesicle 
localization. Neuroscience 56, 539-555. doi: 0306-4522(93)90355-J [pii]. 
Overstreet, D.H. (1986). Selective breeding for increased cholinergic function: development 
of a new animal model of depression. Biol Psychiatry 21, 49-58. doi: 0006-
3223(86)90007-7 [pii]. 
Overstreet, D.H. (2002). Behavioral characteristics of rat lines selected for differential 
hypothermic responses to cholinergic or serotonergic agonists. Behav Genet 32, 335-
348. 
Overstreet, D.H., Friedman, E., Mathe, A.A., and Yadid, G. (2005). The Flinders Sensitive 
Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav 
Rev 29, 739-759. doi: 10.1016/j.neubiorev.2005.03.015. 
Overstreet, D.H., Russell, R.W., Crocker, A.D., and Schiller, G.D. (1984). Selective breeding 
for differences in cholinergic function: pre- and postsynaptic mechanisms involved in 
sensitivity to the anticholinesterase, DFP. Brain Res 294, 327-332. doi: 0006-
8993(84)91044-8 [pii]. 
Overstreet, D.H., Russell, R.W., Helps, S.C., and Messenger, M. (1979). Selective breeding 
for sensitivity to the anticholinesterase DFP. Psychopharmacology (Berl) 65, 15-20. 
 34 
Overstreet, D.H., and Wegener, G. (2013). The Flinders Sensitive Line Rat Model of 
Depression—25 Years and Still Producing. Pharmacological Reviews 65, 143-155. 
doi: 10.1124/pr.111.005397. 
Panula, P., Pirvola, U., Auvinen, S., and Airaksinen, M.S. (1989). Histamine-immunoreactive 
nerve fibers in the rat brain. Neuroscience 28, 585-610. 
Papouin, T., Ladepeche, L., Ruel, J., Sacchi, S., Labasque, M., Hanini, M., Groc, L., 
Pollegioni, L., Mothet, J.P., and Oliet, S.H. (2012). Synaptic and extrasynaptic 
NMDA receptors are gated by different endogenous coagonists. Cell 150, 633-646. 
doi: 10.1016/j.cell.2012.06.029. 
Paul, I.A., Nowak, G., Layer, R.T., Popik, P., and Skolnick, P. (1994). Adaptation of the N-
methyl-D-aspartate receptor complex following chronic antidepressant treatments. J 
Pharmacol Exp Ther 269, 95-102. 
Payne, G.W., and Neuman, R.S. (1997). Effects of hypomagnesia on histamine H1 receptor-
mediated facilitation of NMDA responses. Br J Pharmacol 121, 199-204. doi: 
10.1038/sj.bjp.0701123. 
Pérez-García, C., Morales, L., Cano, M.V., Sancho, I., and Alguacil, L.F. (1999). Effects of 
histamine H3 receptor ligands in experimental models of anxiety and depression. 
Psychopharmacology 142, 215-220. 
Pillot, C., Heron, A., Cochois, V., Tardivel-Lacombe, J., Ligneau, X., Schwartz, J.-C., and 
Arrang, J.-M. (2002). A detailed mapping of the histamine H3 receptor and its gene 
transcripts in rat brain. Neuroscience 114, 173-193. 
Popoli, M., Yan, Z., Mcewen, B.S., and Sanacora, G. (2012). The stressed synapse: the 
impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13, 
22-37. doi: 10.1038/nrn3138. 
Pucilowski, O., Overstreet, D.H., Rezvani, A.H., and Janowsky, D.S. (1993). Chronic mild 
stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol 
Behav 54, 1215-1220. 
Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., Lamantia, A., Mcnamara, J.O., and 
Williams, S.M. (2001). Neuroscience. Sinauer Associates; Sunderland (MA)  
Qiao, H., An, S.C., Ren, W., and Ma, X.M. (2014). Progressive alterations of hippocampal 
CA3-CA1 synapses in an animal model of depression. Behav Brain Res 275, 191-
200. doi: 10.1016/j.bbr.2014.08.040. 
Qin, Y., Zhu, Y., Baumgart, J.P., Stornetta, R.L., Seidenman, K., Mack, V., Van Aelst, L., 
and Zhu, J.J. (2005). State-dependent Ras signaling and AMPA receptor trafficking. 
Genes Dev 19, 2000-2015. doi: 10.1101/gad.342205. 
Racagni, G., and Popoli, M. (2008). Cellular and molecular mechanisms in the long-term 
action of antidepressants. Dialogues Clin Neurosci 10, 385-400. 
Rajkowska, G. (2000). Postmortem studies in mood disorders indicate altered numbers of 
neurons and glial cells. Biol Psychiatry 48, 766-777. doi: S0006-3223(00)00950-1 
[pii]. 
Rajkowska, G., and Miguel-Hidalgo, J.J. (2007). Gliogenesis and glial pathology in 
depression. CNS Neurol Disord Drug Targets 6, 219-233. 
  35 
Reiner, P.B., and Kamondi, A. (1994). Mechanisms of antihistamine-induced sedation in the 
human brain: H1 receptor activation reduces a background leakage potassium current. 
Neuroscience 59, 579-588. 
Richter, J.D., and Klann, E. (2009). Making synaptic plasticity and memory last: mechanisms 
of translational regulation. Genes Dev 23, 1-11. doi: 10.1101/gad.1735809. 
Roman, E., Stewart, R.B., Bertholomey, M.L., Jensen, M.L., Colombo, G., Hyytia, P., Badia-
Elder, N.E., Grahame, N.J., Li, T.K., and Lumeng, L. (2012). Behavioral profiling of 
multiple pairs of rats selectively bred for high and low alcohol intake using the MCSF 
test. Addict Biol 17, 33-46. doi: 10.1111/j.1369-1600.2011.00327.x. 
Roohafza, H.R., Afshar, H., Keshteli, A.H., Mohammadi, N., Feizi, A., Taslimi, M., and 
Adibi, P. (2014). What's the role of perceived social support and coping styles in 
depression and anxiety? J Res Med Sci 19, 944-949. 
Sanacora, G., Treccani, G., and Popoli, M. (2012). Towards a glutamate hypothesis of 
depression: an emerging frontier of neuropsychopharmacology for mood disorders. 
Neuropharmacology 62, 63-77. doi: 10.1016/j.neuropharm.2011.07.036. 
Sander, K., Kottke, T., and Stark, H. (2008). Histamine H3 Receptor Antagonists Go to 
Clinics. Biological & Pharmaceutical Bulletin 31, 2163-2181. 
Saybasili, H., Stevens, D.R., and Haas, H.L. (1995). pH-dependent modulation of N-methyl-
D-aspartate receptor-mediated synaptic currents by histamine in rat hippocampus in 
vitro. Neurosci Lett 199, 225-227. doi: 0304394095120515 [pii]. 
Schiller, G.D., Daws, L.C., Overstreet, D.H., and Orbach, J. (1991). Lack of anxiety in an 
animal model of depression with cholinergic supersensitivity. Brain Res Bull 26, 433-
435. doi: 0361-9230(91)90019-G [pii]. 
Selbach, O., Brown, R.E., and Haas, H.L. (1997). Long-term increase of hippocampal 
excitability by histamine and cyclic AMP. Neuropharmacology 36, 1539-1548. 
Shepherd, J.K., Grewal, S.S., Fletcher, A., Bill, D.J., and Dourish, C.T. (1994). Behavioural 
and pharmacological characterisation of the elevated "zero-maze" as an animal model 
of anxiety. Psychopharmacology (Berl) 116, 56-64. 
Sluyter, F., Korte, S.M., Bohus, B., and Van Oortmerssen, G.A. (1996). Behavioral stress 
response of genetically selected aggressive and nonaggressive wild house mice in the 
shock-probe/defensive burying test. Pharmacol Biochem Behav 54, 113-116. doi: 
0091-3057(95)02164-7 [pii]. 
Smith, K. (2014). Mental health: a world of depression. Nature 515, 181. doi: 
10.1038/515180a. 
Smith, W.B., Starck, S.R., Roberts, R.W., and Schuman, E.M. (2005). Dopaminergic 
Stimulation of Local Protein Synthesis Enhances Surface Expression of GluR1 and 
Synaptic Transmission in Hippocampal Neurons. Neuron 45, 765-779. doi: 
http://dx.doi.org/10.1016/j.neuron.2005.01.015. 
Stahl, S. (2013). Stahl's Essential psychopharmacology: neuroscientific basis and practical 
applications (4th ed.). Cambrige University Press, NY. 
Steimer, T., Driscoll, P., and Schulz, P.E. (1997a). Brain metabolism of progesterone, coping 
behaviour and emotional reactivity in male rats from two psychogenetically selected 
lines. J Neuroendocrinol 9, 169-175. 
 36 
Steimer, T., La Fleur, S., and Schulz, P.E. (1997b). Neuroendocrine correlates of emotional 
reactivity and coping in male rats from the Roman high (RHA/Verh)- and low 
(RLA/Verh)-avoidance lines. Behav Genet 27, 503-512. 
Stewart, A.M., and Kalueff, A.V. (2015). Developing better and more valid animal models of 
brain disorders. Behav Brain Res 276, 28-31. doi: 10.1016/j.bbr.2013.12.024. 
Stockmeier, C.A., Mahajan, G.J., Konick, L.C., Overholser, J.C., Jurjus, G.J., Meltzer, H.Y., 
Uylings, H.B., Friedman, L., and Rajkowska, G. (2004). Cellular changes in the 
postmortem hippocampus in major depression. Biol Psychiatry 56, 640-650. doi: 
10.1016/j.biopsych.2004.08.022. 
Strekalova, T., Couch, Y., Kholod, N., Boyks, M., Malin, D., Leprince, P., and Steinbusch, 
H.M. (2011). Update in the methodology of the chronic stress paradigm: internal 
control matters. Behav Brain Funct 7, 9. doi: 10.1186/1744-9081-7-9. 
Sutton, M.A., Ito, H.T., Cressy, P., Kempf, C., Woo, J.C., and Schuman, E.M. (2006). 
Miniature neurotransmission stabilizes synaptic function via tonic suppression of 
local dendritic protein synthesis. Cell 125, 785-799. doi: 10.1016/j.cell.2006.03.040. 
Sutton, M.A., Taylor, A.M., Ito, H.T., Pham, A., and Schuman, E.M. (2007). Postsynaptic 
decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic 
transmission to local protein synthesis. Neuron 55, 648-661. doi: 
10.1016/j.neuron.2007.07.030. 
Taghzouti, K., Lamarque, S., Kharouby, M., and Simon, H. (1999). Interindividual 
differences in active and passive behaviors in the forced-swimming test: implications 
for animal models of psychopathology. Biol Psychiatry 45, 750-758. doi: 
S0006322398001565 [pii]. 
Takeshita, Y., Watanabe, T., Sakata, T., Munakata, M., Ishibashi, H., and Akaike, N. (1998). 
Histamine modulates high-voltage-activated calcium channels in neurons dissociated 
from the rat tuberomammillary nucleus. Neuroscience 87, 797-805. doi: 
S0306452298001523 [pii]. 
Thomas, G.M., and Huganir, R.L. (2004). MAPK cascade signalling and synaptic plasticity. 
Nat Rev Neurosci 5, 173-183. doi: 10.1038/nrn1346 
Tiligada, E., Kyriakidis, K., Chazot, P.L., and Passani, M.B. (2011). Histamine 
pharmacology and new CNS drug targets. CNS Neurosci Ther 17, 620-628. doi: 
10.1111/j.1755-5949.2010.00212.x. 
Timm, J., Marr, I., Werthwein, S., Elz, S., Schunack, W., and Schlicker, E. (1998). H2 
receptor-mediated facilitation and H3 receptor-mediated inhibition of noradrenaline 
release in the guinea-pig brain. Naunyn Schmiedebergs Arch Pharmacol 357, 232-
239. 
Torrent, A., Moreno-Delgado, D., Gomez-Ramirez, J., Rodriguez-Agudo, D., Rodriguez-
Caso, C., Sanchez-Jimenez, F., Blanco, I., and Ortiz, J. (2005). H3 autoreceptors 
modulate histamine synthesis through calcium/calmodulin- and cAMP-dependent 
protein kinase pathways. Mol Pharmacol 67, 195-203. doi: 10.1124/mol.104.005652. 
Trullas, R., and Skolnick, P. (1990). Functional antagonists at the NMDA receptor complex 
exhibit antidepressant actions. Eur J Pharmacol 185, 1-10. doi: 0014-2999(90)90204-
J [pii]. 
  37 
Turrigiano, G.G., Leslie, K.R., Desai, N.S., Rutherford, L.C., and Nelson, S.B. (1998). 
Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature 391, 
892-896. doi: 10.1038/36103. 
Van Der Vegt, B.J., De Boer, S.F., Buwalda, B., De Ruiter, A.J., De Jong, J.G., and 
Koolhaas, J.M. (2001). Enhanced sensitivity of postsynaptic serotonin-1A receptors 
in rats and mice with high trait aggression. Physiol Behav 74, 205-211. doi: S0031-
9384(01)00565-0 [pii]. 
Van Reenen, C.G., O'connell, N.E., Van Der Werf, J.T., Korte, S.M., Hopster, H., Jones, 
R.B., and Blokhuis, H.J. (2005). Responses of calves to acute stress: individual 
consistency and relations between behavioral and physiological measures. Physiol 
Behav 85, 557-570. doi: 10.1016/j.physbeh.2005.06.015. 
Veenema, A.H., Cremers, T.I., Jongsma, M.E., Steenbergen, P.J., De Boer, S.F., and 
Koolhaas, J.M. (2005). Differences in the effects of 5-HT(1A) receptor agonists on 
forced swimming behavior and brain 5-HT metabolism between low and high 
aggressive mice. Psychopharmacology (Berl) 178, 151-160. doi: 10.1007/s00213-
004-2005-5. 
Veenema, A.H., Meijer, O.C., De Kloet, E.R., and Koolhaas, J.M. (2003). Genetic selection 
for coping style predicts stressor susceptibility. J Neuroendocrinol 15, 256-267. doi: 
986 [pii]. 
Vizuete, M.L., Traiffort, E., Bouthenet, M.L., Ruat, M., Souil, E., Tardivel-Lacombe, J., and 
Schwartz, J.C. (1997). Detailed mapping of the histamine H2 receptor and its gene 
transcripts in guinea-pig brain. Neuroscience 80, 321-343. doi: S0306452297000109 
[pii]. 
Weiger, T., Stevens, D.R., Wunder, L., and Haas, H.L. (1997). Histamine H1 receptors in C6 
glial cells are coupled to calcium-dependent potassium channels via release of 
calcium from internal stores. Naunyn Schmiedebergs Arch Pharmacol 355, 559-565. 
Williams, K. (1994). Subunit-specific potentiation of recombinant N-methyl-D-aspartate 
receptors by histamine. Mol Pharmacol 46, 531-541. 
Yang, Q.Z., and Hatton, G.I. (2002). Histamine H1-receptor modulation of inter-neuronal 
coupling among vasopressinergic neurons depends on nitric oxide synthase activation. 
Brain Res 955, 115-122. doi: S0006899302033747 [pii]. 
Yanovsky, Y., Reymann, K., and Haas, H.L. (1995). pH-dependent facilitation of synaptic 
transmission by histamine in the CA1 region of mouse hippocampus. Eur J Neurosci 
7, 2017-2020. 
Yokoyama, H., and Iinuma, K. (1996). Histamine and Seizures: Implications for the 
Treatment of Epilepsy. CNS Drugs 5, 321-330. 
Zarate, C.A., Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., 
Charney, D.S., and Manji, H.K. (2006). A randomized trial of an N-methyl-D-
aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63, 
856-864. doi: 10.1001/archpsyc.63.8.856. 
 
 
